A Family of Drug Transporters: the Multidrug Resistanc

Journal of the National Cancer Institute
92, 1295-1302
DOI: 10.1093/jnci/92.16.1295

Citation Report

#	Article	IF	Citations
1	Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. International Journal of Oncology, 1992, 33, 1187.	1.4	12
2	Baseline NIH Stroke Scale score strongly predicts outcome after stroke. Neurology, 1999, 53, 126-126.	1.5	1,200
3	New ABC transporters in multi-drug resistance. Expert Opinion on Therapeutic Targets, 2000, 4, 561-580.	1.0	6
4	Mechanisms and clinical implications of renal drug excretion*. Drug Metabolism Reviews, 2001, 33, 299-351.	1.5	114
5	Study of Multi-Drug Resistant Mechanisms in a Taxol-Resistant Hepatocellular Carcinoma QGY-TR 50 Cell Line. Biochemical and Biophysical Research Communications, 2001, 280, 1237-1242.	1.0	19
6	Reactive Oxygen Species-Related Induction of Multidrug Resistance-Associated Protein 2 Expression in Primary Hepatocytes Exposed to Sulforaphane. Biochemical and Biophysical Research Communications, 2001, 282, 257-263.	1.0	64
7	Erythrocyte Membrane ATP Binding Cassette (ABC) Proteins: MRP1 and CFTR as Well as CD39 (Ecto-apyrase) Involved in RBC ATP Transport and Elevated Blood Plasma ATP of Cystic Fibrosis. Blood Cells, Molecules, and Diseases, 2001, 27, 165-180.	0.6	54
8	Monitoring of MRP-like Activity in Human Erythrocytes: Inhibitory Effect of Isoflavones. Blood Cells, Molecules, and Diseases, 2001, 27, 894-900.	0.6	31
9	Mouse Models for Sporadic Cancer. Experimental Cell Research, 2001, 264, 100-110.	1.2	32
10	The interplay of glutathione-related processes in antioxidant defense. Environmental Toxicology and Pharmacology, 2001, 10, 141-152.	2.0	277
11	Anticancer therapy with novel tubulin-interacting drugs. Drug Resistance Updates, 2001, 4, 392-401.	6.5	119
12	Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene, 2001, 273, 89-96.	1.0	143
13	Expression of p-glycoprotein is associated with that of multidrug resistance protein 1 (MRP1) in the vestibular labyrinth and endolymphatic sac of the guinea pig. Neuroscience Letters, 2001, 303, 189-192.	1.0	19
14	PHARMACOGENOMICS: The Inherited Basis for Interindividual Differences in Drug Response. Annual Review of Genomics and Human Genetics, 2001, 2, 9-39.	2.5	365
15	Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Letters, 2001, 503, 179-184.	1.3	52
16	Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1513, 49-54.	1.4	135
17	Metabolism and disposition of the novel antileukaemic drug, benzamide riboside, in the isolated perfused rat liver. Life Sciences, 2001, 69, 2489-2502.	2.0	4
18	Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opinion on Investigational Drugs, 2001, 10, 1099-1115.	1.9	40

#	Article	IF	Citations
19	A Prevention Strategy for Circumventing Drug Resistance in Cancer Chemotherapy. Current Pharmaceutical Design, 2001, 7, 1595-614.	0.9	15
20	Functional Expression of Multidrug Resistance Protein 1 inPichia pastorisâ€. Biochemistry, 2001, 40, 8307-8316.	1.2	28
21	Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics Journal, 2001, 1, 59-64.	0.9	125
22	Characterization of a Human Colorectal Carcinoma Cell Line with Acquired Resistance to Flavopiridol. Molecular Pharmacology, 2001, 60, 885-893.	1.0	19
23	Vectorial Transport by Double-Transfected Cells Expressing the Human Uptake Transporter SLC21A8 and the Apical Export Pump ABCC2. Molecular Pharmacology, 2001, 60, 934-943.	1.0	209
24	MRP8, A New Member of ABC Transporter Superfamily, Identified by EST Database Mining and Gene Prediction Program, Is Highly Expressed in Breast Cancer. Molecular Medicine, 2001, 7, 509-516.	1.9	170
25	The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Annals of Oncology, 2001, 12, 1239-1245.	0.6	37
26	Drug resistance in hematologic malignancies. Current Opinion in Oncology, 2001, 13, 463-469.	1.1	67
27	Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Annals of Oncology, 2001, 12, 1515-1525.	0.6	33
28	Expression of functional lung resistanceâ€“related protein predicts poor outcome in adult T-cell leukemia. Blood, 2001, 98, 1160-1165.	0.6	70
29	Mutation of Trp1254 in the Multispecific Organic Anion Transporter, Multidrug Resistance Protein 2 (MRP2) (ABCC2), Alters Substrate Specificity and Results in Loss of Methotrexate Transport Activity. Journal of Biological Chemistry, 2001, 276, 38108-38114.	1.6	111
30	MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics and Genomics, 2001, 11, 217-221.	5.7	373
31	Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 2001, 167, 3-23.	2.0	364
32	Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology, 2001, 167, 37-46.	2.0	61
33	Expression of MRP1 and related transporters in human lung cells in culture. Toxicology, 2001, 167, 59-72.	2.0	48
34	Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy. Epilepsia, 2001, 42, 1501-1506.	2.6	409
35	Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine, 2001, 250, 186-200.	2.7	226
36	Influence of Multidrug Resistance (MDR) Proteins at the Bloodâ€“Brain Barrier on the Transport and Brain Distribution of Enaminone Anticonvulsants. Journal of Pharmaceutical Sciences, 2001, 90, 1540-1552.	1.6	46

#	Article	IF	Citations
37	Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function. International Journal of Cancer, 2001, 93, 107-113.	2.3	59
38	Induction ofMRP5 andSMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. International Journal of Cancer, 2001, 94, 432-437.	2.3	31
39	Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. International Journal of Cancer, 2001, 94, 492-499.	2.3	163
40	A critical evaluation of the brain efflux index method as applied to the nitric oxide synthase inhibitor, aminoguanidine. Biopharmaceutics and Drug Disposition, 2001, 22, 391-401.	1.1	2
41	Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences, 2001, 90, 397-421.	1.6	248
42	Proteomics for studying cancer cells and the development of chemoresistance. Proteomics, 2001, 1, 1233-1248.	1.3	50
43	Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Molecular and Cellular Biochemistry, 2001, 219, 51-56.	1.4	21
44	Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer and Metastasis Reviews, 2001, 20, 13-25.	2.7	123
45	ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics, 2001, 2, 51-64.	0.6	186
48	From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and Molecular Life Sciences, 2001, 58, 931-959.	2.4	591
49	Hammerhead ribozyme against Î³-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Therapy, 2001, 8, 803-814.	2.2	41
50	Pharmacogenetics and cancer therapy. Nature Reviews Cancer, 2001, 1, 99-108.	12.8	227
51	Cyclosporin A inhibits the extrusion pump function of p-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin. Brain Research, 2001, 901, 265-270.	1.1	23
52	Identification of two putative ATP-cassette genes in Encephalitozoon intestinalis. International Journal for Parasitology, 2001, 31, 1681-1685.	1.3	9
53	Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discovery Today, 2001, 6, 835-839.	3.2	85
54	Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3). Journal of Biological Chemistry, 2001, 276, 46400-46407.	1.6	227
55	The Leishmania ATP-binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase. Journal of Biological Chemistry, 2001, 276, 26301-26307.	1.6	205
56	Identification of the Apical Membrane-targeting Signal of the Multidrug Resistance-associated Protein 2 (MRP2/cMOAT). Journal of Biological Chemistry, 2001, 276, 20876-20881.	1.6	54

#	Article	IF	Citations
57	Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9431-9436.	3.3	115
58	Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11283-11288.	3.3	94
59	Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1. Journal of Biological Chemistry, 2001, 276, 39359-39367.	1.6	202
60	Short Communication:Expression of P-Glycoprotein and Multidrug Resistance-Associated Protein in Healthy Volunteers and HIV-Infected Patients. AIDS Research and Human Retroviruses, 2001, 17, 1329-1332.	0.5	43
61	Requirement of the N-Terminal Extension for Vacuolar Trafficking and Transport Activity of Yeast Ycf1p, an ATP-binding Cassette Transporter. Molecular Biology of the Cell, 2002, 13, 4443-4455.	0.9	60
62	Pluronic P85 Block Copolymer Enhances Opioid Peptide Analgesia. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 760-767.	1.3	33
63	MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6997-7002.	3.3	116
64	Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein. British Journal of Cancer, 2002, 86, 954-962.	2.9	5
65	Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells. British Journal of Cancer, 2002, 86, 1943-1950.	2.9	15
66	Thiopurine Metabolism and Identification of the Thiopurine Metabolites Transported by MRP4 and MRP5 Overexpressed in Human Embryonic Kidney Cells. Molecular Pharmacology, 2002, 62, 1321-1331.	1.0	174
67	Charged Amino Acids in the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) Are Critical Determinants of Transport Activity. Journal of Biological Chemistry, 2002, 277, 41326-41333.	1.6	65
68	Characteristics of the Fetal/Maternal Interface with Potential Usefulness in the Development of Future Immunological and Pharmacological Strategies. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 402-409.	1.3	34
69	The Fluorescent Probe Bodipy-FL-Verapamil Is a Substrate for Both P-glycoprotein and Multidrug Resistance-related Protein (MRP)-1. Journal of Histochemistry and Cytochemistry, 2002, 50, 731-734.	1.3	29
70	Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations. Journal of Clinical Oncology, 2002, 20, 81-87.	0.8	55
71	Microtubule alterations and resistance to tubulin-binding agents (Review). International Journal of Oncology, 2002, 21, 621.	1.4	33
72	Loss of ATP-dependent Transport Activity in Pseudoxanthoma Elasticum-associated Mutants of Human ABCC6 (MRP6). Journal of Biological Chemistry, 2002, 277, 16860-16867.	1.6	216
73	Expression of MRP4 Confers Resistance to Ganciclovir and Compromises Bystander Cell Killing. Journal of Biological Chemistry, 2002, 277, 38998-39004.	1.6	101
74	Transporter Gene Expression in Lactating and Nonlactating Human Mammary Epithelial Cells Using Real-Time Reverse Transcription-Polymerase Chain Reaction. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 487-496.	1.3	136

#	Article	IF	Citations
75	Enzymes of the Trypanothione Metabolism as Targets for Antitrypanosomal Drug Development. Current Topics in Medicinal Chemistry, 2002, 2, 1239-1259.	1.0	107
76	Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics. Current Drug Metabolism, 2002, 3, 1-12.	0.7	18
77	Pharmacogenetics in diverse ethnic populations â€“ implications for drug discovery and development. Pharmacogenomics, 2002, 3, 493-506.	0.6	13
78	Inhibition of the Multidrug Resistance Protein 1 (MRP1) by Peptidomimetic Glutathione-Conjugate Analogs. Molecular Pharmacology, 2002, 62, 1160-1166.	1.0	38
79	Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview. Oncologist, 2002, 7, 516-530.	1.9	107
80	Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological Approaches. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1096-1104.	1.3	40
81	Reconstitution of Transport-Active Multidrug Resistance Protein 2 (MRP2; ABCC2) in Proteoliposomes. Biological Chemistry, 2002, 383, 1001-9.	1.2	13
82	Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. Journal of Biological Chemistry, 2002, 277, 47980-47990.	1.6	187
83	Multiple Membrane-associated Tryptophan Residues Contribute to the Transport Activity and Substrate Specificity of the Human Multidrug Resistance Protein, MRP1. Journal of Biological Chemistry, 2002, 277, 49495-49503.	1.6	45
84	Localization, Regulation, and Substrate Transport Properties of Bpt1p, a Saccharomyces cerevisiae MRP-Type ABC Transporter. Eukaryotic Cell, 2002, 1, 391-400.	3.4	92
85	A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics and Genomics, 2002, 12, 321-330.	5.7	112
86	Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 2002, 16, 2295-2301.	1.0	198
87	Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Current Opinion in Infectious Diseases, 2002, 15, 3-8.	1.3	29
88	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochemical Journal, 2002, 361, 497.	1.7	79
89	Impaired 2â€²,3â€²-dideoxy-3â€²-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochemical Journal, 2002, 368, 325-332.	1.7	29
90	High cellular accumulation of sulphoraphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. Biochemical Journal, 2002, 364, 301-307.	1.7	132
91	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochemical Journal, 2002, 361, 497-503.	1.7	130
92	Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain, 2002, 125, 22-31.	3.7	465

#	Article	IF	Citations
93	C-7 Analogues of Progesterone as Potent Inhibitors of the P-Glycoprotein Efflux Pump. Journal of Medicinal Chemistry, 2002, 45, 390-398.	2.9	29
94	Nucleotide Binding and Nucleotide Hydrolysis Properties of the ABC Transporter MRP6 (ABCC6)â€. Biochemistry, 2002, 41, 8058-8067.	1.2	34
95	Helicobacter bilis Infection Accelerates and H. hepaticus Infection Delays the Development of Colitis in Multiple Drug Resistance-Deficient (mdr1aâ¯/â¯) Mice. American Journal of Pathology, 2002, 160, 739-751.	1.9	138
96	Determinants of the Substrate Specificity of Multidrug Resistance Protein 1. Journal of Biological Chemistry, 2002, 277, 20934-20941.	1.6	43
97	Expression of Multidrug Resistance GenesMVP,MDR1, andMRP1Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients. Journal of Clinical Oncology, 2002, 20, 3282-3292.	0.8	43
98	Mechanisms of Cancer Drug Resistance. Annual Review of Medicine, 2002, 53, 615-627.	5.0	2,284
99	OVEREXPRESSION OF IL-6 BUT NOT IL-8 INCREASES PACLITAXEL RESISTANCE OF U-2OS HUMAN OSTEOSARCOMA CELLS. Cytokine, 2002, 17, 234-242.	1.4	67
100	Induction of Apoptosis by Chemotherapeutic Drugs without Generation of Reactive Oxygen Species. Archives of Biochemistry and Biophysics, 2002, 397, 262-272.	1.4	53
101	Ethnicity and Pharmacogenomics. , 0, , 489-514.		1
102	The Mucosa of the Small Intestine. Clinical Pharmacokinetics, 2002, 41, 235-253.	1.6	208
103	Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. Clinical Pharmacokinetics, 2002, 41, 813-851.	1.6	272
104	Theoretical Predictions of Drug Absorption in Drug Discovery and Development. Clinical Pharmacokinetics, 2002, 41, 877-899.	1.6	60
105	Multidrug Resistance II: MRP and Related Proteins. , 2002, , 255-267.		1
106	Mammalian ABC Transporters in Health and Disease. Annual Review of Biochemistry, 2002, 71, 537-592.	5.0	1,441
107	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. Molecular Pharmacology, 2002, 62, 1-6.	1.0	154
108	DNA Topoisomerase II as a Target for Cancer Chemotherapy. Cancer Investigation, 2002, 20, 570-589.	0.6	127
109	Transport of leukotriene C4 and structurally related conjugates. Vitamins and Hormones, 2002, 64, 153-184.	0.7	48
110	GLUTATHIONE CONJUGATES AND THEIR SYNTHETIC DERIVATIVES AS INHIBITORS OF GLUTATHIONE-DEPENDENT ENZYMES INVOLVED IN CANCER AND DRUG RESISTANCE. Drug Metabolism Reviews, 2002, 34, 821-863.	1.5	65

#	Article	IF	Citations
111	Hypochlorous acid inhibits glutathione S-conjugate export from human erythrocytes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 479-486.	1.4	8
112	Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1567, 133-142.	1.4	23
113	In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochemical and Biophysical Research Communications, 2002, 293, 100-105.	1.0	37
114	Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci, 2002, 4, 22-30.	1.3	90
115	Evidence for the Role of Glycosylation in Accessibility of the Extracellular Domains of Human MRP1 (ABCC1). Biochemistry, 2002, 41, 10123-10132.	1.2	52
116	Overexpression of Î³-glutamylcysteine synthetase in human malignant mesothelioma. Human Pathology, 2002, 33, 748-755.	1.1	31
117	Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. European Journal of Cancer, 2002, 38, 1535-1542.	1.3	34
118	Structureâ€“activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. European Journal of Cancer, 2002, 38, 1661-1670.	1.3	41
119	Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 7-14.	1.3	374
122	Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations. Journal of Clinical Oncology, 2002, 20, 81-87.	0.8	93
123	Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy. American Journal of Physiology - Renal Physiology, 2002, 283, G757-G766.	1.6	68
124	Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. American Journal of Physiology - Renal Physiology, 2002, 282, G540-G548.	1.6	55
125	Combinations Against Combinations: Associations of Anti-HIV 1 Reverse Transcriptase Drugs Challenged by Constellations of Drug Resistance Mutations. Current Drug Metabolism, 2002, 3, 73-95.	0.7	25
126	From blood to bile: recent advances in hepatobiliary transport. Annals of Hepatology, 2002, 1, 64-71.	0.6	15
128	Despite some expression of folate receptor Î± in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 862-868.	0.4	8
129	Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). European Journal of Pharmacology, 2002, 437, 9-17.	1.7	28
130	The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco, 2002, 57, 385-415.	0.9	156
131	The Cryptosporidium parvum ABC protein familyâ˜†. Molecular and Biochemical Parasitology, 2002, 120, 157-161.	0.5	39

#	Article	IF	Citations
132	Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. Journal of Controlled Release, 2002, 78, 43-54.	4.8	171
133	Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. Journal of Immunological Methods, 2002, 262, 159-165.	0.6	47
134	Prediction of intestinal permeability. Advanced Drug Delivery Reviews, 2002, 54, 273-289.	6.6	276
135	Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Advanced Drug Delivery Reviews, 2002, 54, 1311-1331.	6.6	205
136	Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Advanced Drug Delivery Reviews, 2002, 54, 1333-1342.	6.6	54
137	Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochemical Pharmacology, 2002, 63, 333-341.	2.0	34
138	Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochemical Pharmacology, 2002, 63, 2169-2180.	2.0	53
139	3â€²-Azido-2â€²,3â€²-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochemical Pharmacology, 2002, 64, 239-246.	2.0	15
140	Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochemical Pharmacology, 2002, 64, 1569-1578.	2.0	144
141	Aluminum citrate uptake by immortalized brain endothelial cells: implications for its bloodâ€“brain barrier transport. Brain Research, 2002, 930, 101-110.	1.1	55
142	Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the bloodâ€“brain barrier. Vascular Pharmacology, 2002, 38, 339-348.	1.0	191
143	Human T-cell lymphotropic virus type I Tax activates lung resistance-related protein expression in leukemic clones established from an adult T-cell leukemia patient. Experimental Hematology, 2002, 30, 340-345.	0.2	14
144	Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Medicinal Research Reviews, 2002, 22, 512-529.	5.0	158
145	Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharmaceutics and Drug Disposition, 2002, 23, 361-367.	1.1	29
146	Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. International Journal of Cancer, 2002, 97, 732-739.	2.3	27
147	Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. International Journal of Cancer, 2002, 98, 173-180.	2.3	72
148	Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2002, 128, 349-357.	1.2	43
149	Relevance of Multidrug Resistance Proteins for Intestinal Drug Absorptionin vitroandin vivo. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 5-13.	0.0	58

#	Article	IF	Citations
150	High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. British Journal of Haematology, 2002, 116, 834-838.	1.2	52
151	Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology, 2002, 41, 65-74.	1.6	100
152	Functional analysis of a vacuolar ABC transporter in wild-typeCandida albicansreveals its involvement in virulence. Molecular Microbiology, 2002, 43, 571-584.	1.2	55
153	Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Molecular Microbiology, 2002, 43, 1129-1138.	1.2	93
154	Proteoglycans mediate malaria sporozoite targeting to the liver. Molecular Microbiology, 2002, 45, 637-651.	1.2	113
155	Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. Journal of Neurochemistry, 2002, 82, 716-719.	2.1	120
156	Mice lacking the multidrug resistance protein 1 have a transiently impaired immune response during tuberculosis. Clinical and Experimental Immunology, 2002, 130, 32-36.	1.1	14
157	S-Decyl-glutathione nonspecifically stimulates the ATPase activity of the nucleotide-binding domains of the human multidrug resistance-associated protein, MRP1 (ABCC1). FEBS Journal, 2002, 269, 3470-3478.	0.2	7
158	Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Therapy, 2002, 9, 579-586.	2.2	48
159	Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia, 2002, 16, 1886-1887.	3.3	13
160	Tissue Distribution and Induction of Human Multidrug Resistant Protein 3. Laboratory Investigation, 2002, 82, 193-201.	1.7	250
161	MRP6 (ABCC6) Detection in Normal Human Tissues and Tumors. Laboratory Investigation, 2002, 82, 515-518.	1.7	458
162	Multidrug resistance in cancer: role of ATPâ€“dependent transporters. Nature Reviews Cancer, 2002, 2, 48-58.	12.8	4,873
163	Pxr, car and drug metabolism. Nature Reviews Drug Discovery, 2002, 1, 259-266.	21.5	438
164	In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. British Journal of Cancer, 2002, 86, 1652-1657.	2.9	531
165	Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (â^'/â^') mice. British Journal of Pharmacology, 2002, 135, 2038-2046.	2.7	47
166	The use of Tris-Lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P-glycoprotein or MRP1. British Journal of Pharmacology, 2002, 137, 1280-1286.	2.7	8
167	A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles. Analytical Biochemistry, 2002, 310, 61-66.	1.1	32

#	Article	IF	Citations
168	Chronic Arsenic-Exposed Human Prostate Epithelial Cells Exhibit Stable Arsenic Tolerance: Mechanistic Implications of Altered Cellular Glutathione and Glutathione S-transferase. Toxicology and Applied Pharmacology, 2002, 183, 99-107.	1.3	61
169	The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biology and Toxicology, 2002, 18, 221-233.	2.4	78
170	Sphingolipids in neuroblastoma: their role in drug resistance mechanisms. Neurochemical Research, 2002, 27, 665-674.	1.6	21
171	Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharmaceutical Research, 2002, 19, 1509-1515.	1.7	53
172	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer and Metastasis Reviews, 2002, 21, 167-183.	2.7	42
173	Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharmaceutical Research, 2003, 20, 618-623.	1.7	83
174	Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharmaceutical Research, 2003, 20, 904-909.	1.7	61
175	Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharmaceutical Research, 2003, 20, 1394-1400.	1.7	80
176	Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology, 2003, 38, 374-384.	3.6	306
177	Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases, 2003, 42, 906-925.	2.1	103
178	Hepatobiliary transport of a nonpeptidic endothelin antagonist, (+)-(5S,6R,7R)-2-butyl-7-[2((2S)-2-carboxypropyl)-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl) cyclopentenol[1,2-b]pyridine-6-carboxylic acid: uptake by isolated rat hepatocytes and canalicular membrane vesicles. Pharmaceutical Research, 2003, 20, 89-95.	1.7	6
179	Multidrug resistanceâ€associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. BioFactors, 2003, 17, 103-114.	2.6	183
180	Biochemical Modulation of Cisplatin Mechanisms of Action:â€‰ Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chemical Reviews, 2003, 103, 645-662.	23.0	796
181	THEROLE OFDRUGTRANSPORTERS AT THEBLOOD-BRAINBARRIER. Annual Review of Pharmacology and Toxicology, 2003, 43, 629-656.	4.2	221
182	A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemotherapy and Pharmacology, 2003, 51, 107-118.	1.1	42
183	Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology, 2003, 51, 297-305.	1.1	35
184	Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1024-1031.	3.3	24
185	The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochemical Pharmacology, 2003, 65, 765-771.	2.0	67

#	Article	IF	Citations
186	Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels. Biochemical Pharmacology, 2003, 66, 809-817.	2.0	50
187	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2003, 55, 3-29.	6.6	1,259
188	Efflux transporters of the human placenta. Advanced Drug Delivery Reviews, 2003, 55, 125-132.	6.6	148
189	Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Advanced Drug Delivery Reviews, 2003, 55, 133-150.	6.6	121
190	PluronicÂ® block copolymers as modulators of drug efflux transporter activity in the bloodâ€“brain barrier. Advanced Drug Delivery Reviews, 2003, 55, 151-164.	6.6	296
191	Interactions between doxorubicin and the human iron regulatory system. Biochimica Et Biophysica Acta - Molecular Cell Research, 2003, 1593, 209-218.	1.9	23
192	Multidrug resistance proteins in rhabdomyosarcomas. Cancer, 2003, 97, 1999-2005.	2.0	39
193	Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. International Journal of Cancer, 2003, 103, 752-758.	2.3	12
194	Natural mechanisms protecting against cancer. Immunology Letters, 2003, 90, 103-122.	1.1	181
195	Unique reciprocal changes of hepatocellular membrane transporter expression and fluidity in rats with selective biliary obstruction. Hepatology Research, 2003, 26, 157-163.	1.8	8
196	Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 791, 291-303.	1.2	23
197	Covalent binding to glutathione of the DNA-alkylating antitumor agent, S23906-1. FEBS Journal, 2003, 270, 2848-2859.	0.2	27
198	Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Development Growth and Differentiation, 2003, 45, 377-387.	0.6	53
199	Evidence for an active transport of morphine-6-Î²-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. Journal of Neurochemistry, 2003, 86, 1564-1567.	2.1	129
200	Side Population Keratinocytes Resembling Bone Marrow Side Population Stem Cells Are Distinct From Label-Retaining Keratinocyte Stem Cells. Journal of Investigative Dermatology, 2003, 121, 1095-1103.	0.3	92
201	Arsenate transport and reduction in the hyper-tolerant fungus Aspergillus sp. P37. Environmental Microbiology, 2003, 5, 1087-1093.	1.8	30
202	Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer, 2003, 13, 701-734.	1.2	43
203	Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. British Journal of Cancer, 2003, 88, 879-886.	2.9	42

#	Article	IF	Citations
204	Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. British Journal of Cancer, 2003, 88, 1963-1970.	2.9	118
205	ABCC6/MRP6 mutations: further insight into the molecular pathology of pseudoxanthoma elasticum. European Journal of Human Genetics, 2003, 11, 215-224.	1.4	57
206	Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265-7279.	2.6	2,838
207	Resistance to antifolates. Oncogene, 2003, 22, 7431-7457.	2.6	249
208	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	2.6	956
209	Strategies for reversing drug resistance. Oncogene, 2003, 22, 7512-7523.	2.6	339
210	Multidrug resistance transporters in the olfactory receptor neurons of Xenopus laevis tadpoles. Journal of Physiology, 2003, 546, 375-385.	1.3	52
211	Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer, 2003, 3, 502-516.	12.8	1,005
212	ATP binding cassette transporters and drug resistance in breast cancer.. Endocrine-Related Cancer, 2003, 10, 43-73.	1.6	215
213	Interplay between MRP Inhibition and Metabolism of MRP Inhibitors:Â The Case of Curcumin. Chemical Research in Toxicology, 2003, 16, 1642-1651.	1.7	108
214	Modulation of P-Glycoprotein-Mediated Multidrug Resistance by Flavonoid Derivatives and Analogues. Journal of Medicinal Chemistry, 2003, 46, 2125-2131.	2.9	107
215	Pharmacogenomics â€" Drug Disposition, Drug Targets, and Side Effects. New England Journal of Medicine, 2003, 348, 538-549.	13.9	1,609
216	SOLVING THE PROBLEM OF MULTIDRUG RESISTANCE: ABC TRANSPORTERS IN CLINICAL ONCOLOGY. , 2003, , 359-391.		14
217	THE MULTIDRUG RESISTANCE PROTEINS 3â€“7. , 2003, , 445-458.		6
218	ABC-transporters: implications on drug resistance from microorganisms to human cancers. International Journal of Antimicrobial Agents, 2003, 22, 188-199.	1.1	255
219	ABC transporters and drug resistance in parasitic protozoa. International Journal of Antimicrobial Agents, 2003, 22, 301-317.	1.1	71
220	Multidrug Resistance Protein (MRP) 1 and MRP3 Attenuate Cytotoxic and Transactivating Effects of the Cyclopentenone Prostaglandin, 15-Deoxy-Î”12,14Prostaglandin J2in MCF7 Breast Cancer Cellsâ€. Biochemistry, 2003, 42, 5429-5437.	1.2	73
221	Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human Heart. American Journal of Pathology, 2003, 163, 1567-1577.	1.9	89

#	Article	IF	Citations
222	Characterization of the Role of Polar Amino Acid Residues within Predicted Transmembrane Helix 17 in Determining the Substrate Specificity of Multidrug Resistance Protein 3â€. Biochemistry, 2003, 42, 9989-10000.	1.2	33
223	Overexpression, purification, and functional characterization of ATP-binding cassette transporters in the yeast, Pichia pastoris. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1610, 63-76.	1.4	29
224	The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents. Biochemical and Biophysical Research Communications, 2003, 303, 1135-1141.	1.0	7
225	Conjugation of chlorambucil with GSH by GST purified from human colon adenocarcinoma cells and its inhibition by plant polyphenols. Life Sciences, 2003, 72, 2629-2640.	2.0	22
226	Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Survey of Ophthalmology, 2003, 48, 424-438.	1.7	149
227	Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in Wistar and TRâ˜† rats: evidence for mrp2 as carrier for oligodeoxynucleotides. Biochemical Pharmacology, 2003, 66, 565-577.	2.0	13
228	The Drosophila melanogaster multidrug-resistance protein 1 (MRP1) homolog has a novel gene structure containing two variable internal exons. Gene, 2003, 307, 41-50.	1.0	27
229	Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience, 2003, 121, 605-617.	1.1	50
230	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates, 2003, 6, 71-84.	6.5	207
231	HUMAN AND DROSOPHILA ABC PROTEINS. , 2003, , 47-61.		5
232	Canalicular multispecific organic anion transporter ABCC2. , 2003, , 263-289.		2
233	The Role of ABC Transporters in Clinical Practice. Oncologist, 2003, 8, 411-424.	1.9	708
234	Multidrug resistance proteins in rheumatoid arthritis, role in diseaseâ€modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scandinavian Journal of Rheumatology, 2003, 32, 381-387.	0.6	0
235	ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics. Journal of Biological Chemistry, 2003, 278, 22644-22649.	1.6	302
236	Gene Variants Affecting Bioavailability of Drugs: Towards Individualized Immunosuppressive Therapy?. Journal of the American Society of Nephrology: JASN, 2003, 14, 1955-1957.	3.0	7
237	Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 524-530.	1.3	46
238	Glutathione Pathways in the Brain. Biological Chemistry, 2003, 384, 505-16.	1.2	514
239	Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut, 2003, 52, 10ii-18.	6.1	33

#	Article	IF	Citations
240	INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3. Drug Metabolism and Disposition, 2003, 31, 773-775.	1.7	18
241	INDUCTION OF MULTIDRUG RESISTANCE PROTEIN 3 IN RAT LIVER IS ASSOCIATED WITH ALTERED VECTORIAL EXCRETION OF ACETAMINOPHEN METABOLITES. Drug Metabolism and Disposition, 2003, 31, 1176-1186.	1.7	78
242	Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Annals of Oncology, 2003, 14, 825-832.	0.6	79
243	Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9108-9110.	3.3	17
244	Cellular Uptake and Efflux of the Tea Flavonoid (-)Epicatechin-3-gallate in the Human Intestinal Cell Line Caco-2. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 745-752.	1.3	229
245	Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	167
246	Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis. Journal of Clinical Oncology, 2003, 21, 4239-4247.	0.8	76
247	Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Human Molecular Genetics, 2003, 12, 99-109.	1.4	60
248	A single point mutation in Drosophila dihydrofolate reductase confers methotrexate resistance to a transgenic CHO cell line. Genome, 2003, 46, 707-715.	0.9	4
249	Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opinion on Biological Therapy, 2003, 3, 23-44.	1.4	36
250	Pumping of Drugs by P-Glycoprotein: A Two-Step Process?. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 846-853.	1.3	54
251	Chemosensitization of Plasmodium falciparum by Probenecid In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 2108-2112.	1.4	57
252	Functional Complementation between a Novel Mammalian Polygenic Transport Complex and an Evolutionarily Ancient Organic Solute Transporter, OSTÎ±-OSTÎ². Journal of Biological Chemistry, 2003, 278, 27473-27482.	1.6	157
253	Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1). Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 643-653.	1.3	50
254	Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	177
255	Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species ofPlasmodium. Redox Report, 2003, 8, 276-279.	1.4	50
256	Biogenesis and cellular dynamics of aminoglycerophospholipids. International Review of Cytology, 2003, 225, 273-323.	6.2	30
257	Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy. Current Drug Targets, 2003, 4, 297-304.	1.0	75

#	Article	IF	Citations
258	Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. International Journal of Oncology, 2003, 22, 1057.	1.4	9
259	Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: Collateral sensitivity to azidothymidine. International Journal of Oncology, 2003, 23, 173.	1.4	8
260	Is Refractory Epilepsy Due to Genetically Determined Resistance to Antiepileptic Drugs?. New England Journal of Medicine, 2003, 348, 1480-1482.	13.9	23
261	Evaluation of MRP1-5 Gene Expression in Cystic Fibrosis Patients Homozygous for the Î”F508 Mutation. Pediatric Research, 2003, 54, 627-634.	1.1	27
262	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochemical Journal, 2003, 371, 361-367.	1.7	291
264	Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. American Journal of Physiology - Renal Physiology, 2003, 284, G280-G289.	1.6	23
266	Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood, 2003, 102, 246-253.	0.6	22
267	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood, 2003, 102, 1202-1210.	0.6	84
268	The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 2003, 102, 4493-4498.	0.6	87
269	Biochemical characterization and NMR studies of the nucleotide-binding domain 1 of multidrug-resistance-associated protein 1: evidence for interaction between ATP and Trp653. Biochemical Journal, 2003, 376, 749-756.	1.7	22
270	Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochemical Journal, 2003, 369, 23-30.	1.7	93
271	Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA?. Annals of the Rheumatic Diseases, 2003, 62, 591-591.	0.5	10
273	Intracellular Localization is a Cofactor for the Phototoxicity of Protoporphyrin IX in the Gastrointestinal Tract: In Vitro StudyÂ¶â€. Photochemistry and Photobiology, 2003, 78, 393.	1.3	15
274	Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. American Journal of Physiology - Renal Physiology, 2003, 285, G602-G610.	1.6	12
275	Efflux Mechanisms in the Central Nervous System: A Powerful Influence on Drug Distribution within the Brain. , 2004, , 83-97.		12
276	Mrp2 is involved in benzylpenicillin-induced choleresis. American Journal of Physiology - Renal Physiology, 2004, 287, G42-G49.	1.6	30
277	Placental Drug Transporters. Current Drug Metabolism, 2004, 5, 125-131.	0.7	106
278	Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy. Current Topics in Medicinal Chemistry, 2004, 4, 1383-1396.	1.0	87

#	Article	IF	Citations
279	Spatial Composition of Prostate Cancer Spheroids in Mixed and Static Cultures. Tissue Engineering, 2004, 10, 1266-1276.	4.9	44
280	Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 449-455.	1.3	168
281	Mutations of Charged Amino Acids in or near the Transmembrane Helices of the Second Membrane Spanning Domain Differentially Affect the Substrate Specificity and Transport Activity of the Multidrug Resistance Protein MRP1 (ABCC1). Molecular Pharmacology, 2004, 65, 1375-1385.	1.0	71
282	The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood, 2004, 104, 3603-3610.	0.6	163
283	Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Annals of Oncology, 2004, 15, 1805-1809.	0.6	31
284	Principles of pharmacogeneticsâ€"implications for the anaesthetist. British Journal of Anaesthesia, 2004, 93, 440-450.	1.5	35
285	Mitochondria in tumor cells studied by laser scanning confocal microscopy. Journal of Biomedical Optics, 2004, 9, 385.	1.4	38
286	The intracellular pharmacology of antiretroviral protease inhibitors. Journal of Antimicrobial Chemotherapy, 2004, 54, 982-990.	1.3	93
287	Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis. Journal of Biological Chemistry, 2004, 279, 48855-48864.	1.6	49
288	Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats. Toxicological Sciences, 2004, 82, 478-487.	1.4	83
289	Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil Cytotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 260-267.	1.3	88
290	ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1204-1212.	1.3	29
291	Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter. Antimicrobial Agents and Chemotherapy, 2004, 48, 2673-2682.	1.4	52
292	Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions. Journal of Biological Chemistry, 2004, 279, 12325-12336.	1.6	63
294	The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics, 2004, 5, 67-99.	0.6	75
295	Nonsteroidal Anti-Inflammatory Drugs Potentiate 1-Methyl-4-phenylpyridinium (MPP+)-Induced Cell Death by Promoting the Intracellular Accumulation of MPP+in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 800-807.	1.3	21
296	Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R1505-R1516.	0.9	57
297	Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Annals of the Rheumatic Diseases, 2004, 63, 131-137.	0.5	33

#	Article	IF	Citations
298	Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFÂ. Annals of the Rheumatic Diseases, 2004, 63, 138-143.	0.5	76
300	Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 156-164.	1.3	98
301	Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport. Physiological Reviews, 2004, 84, 987-1049.	13.1	377
302	Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU International, 2004, 93, 1333-1338.	1.3	28
303	Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Tropical Medicine and International Health, 2004, 9, 606-614.	1.0	29
304	Watson and Crick 50 years on. From double helix to pharmacogenomics. Anaesthesia, 2004, 59, 150-165.	1.8	9
305	The dMRP/CG6214 gene of Drosophila is evolutionarily and functionally related to the human multidrug resistance-associated protein family. Insect Molecular Biology, 2004, 13, 539-548.	1.0	35
306	Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia, 2004, 18, 385-393.	3.3	97
307	Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidinâ„¢. British Journal of Cancer, 2004, 91, 1405-1413.	2.9	24
308	Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. British Journal of Pharmacology, 2004, 143, 856-864.	2.7	132
309	Emerging contaminantsâ€"pesticides, PPCPs, microbial degradation products and natural substances as inhibitors of multixenobiotic defense in aquatic organisms. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 552, 101-117.	0.4	171
310	Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. Trends in Parasitology, 2004, 20, 109-112.	1.5	28
311	Pharmacogenomics and renal drug disposition in the newborn. Seminars in Perinatology, 2004, 28, 132-140.	1.1	23
312	The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Research, 2004, 62, 1-7.	1.9	51
313	Analysis of MVP and VPARP promoters indicates a role for chromatin remodeling in the regulation of MVP. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1678, 33-46.	2.4	7
314	Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochemical Pharmacology, 2004, 67, 31-39.	2.0	57
315	Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochemical Pharmacology, 2004, 67, 503-511.	2.0	81
316	Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochemical Pharmacology, 2004, 67, 1607-1617.	2.0	103

#	Article	IF	Citations
317	Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochemical Pharmacology, 2004, 68, 911-921.	2.0	38
318	Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters. Biochemical Pharmacology, 2004, 68, 1401-1410.	2.0	59
319	The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines. Biochemical Pharmacology, 2004, 68, 1815-1823.	2.0	5
320	Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chemico-Biological Interactions, 2004, 147, 233-246.	1.7	119
321	Mining our ABCs. Cancer Cell, 2004, 6, 105-107.	7.7	41
322	The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells. Cancer Detection and Prevention, 2004, 28, 283-293.	2.1	4
323	Efflux transport systems for organic anions and cations at the blood?CSF barrier. Advanced Drug Delivery Reviews, 2004, 56, 1741-1763.	6.6	99
324	Potential role of ABC transporters as a detoxification system at the blood?CSF barrier. Advanced Drug Delivery Reviews, 2004, 56, 1793-1809.	6.6	154
325	Determination of Carrier-Mediated Transport of 2Â,3Â-Dideoxypurine Nucleosides in the Rat Ileum Using a Bidirectional Perfusion Technique. Pharmaceutical Research, 2004, 21, 300-308.	1.7	2
326	Involvement of P-Glycoprotein in the Transport of Saquinavir and Indinavir in Rat Brain Microvessel Endothelial and Microglia Cell Lines. Pharmaceutical Research, 2004, 21, 811-818.	1.7	43
327	Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathology and Oncology Research, 2004, 10, 133-141.	0.9	36
328	A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry, 2004, 98, 1599-1606.	1.5	26
329	Effect of Organic Isothiocyanates on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Pharmaceutical Research, 2004, 21, 2261-2269.	1.7	40
330	New oral drugs in older patients: a review of idarubicin in elderly patients. Critical Reviews in Oncology/Hematology, 2004, 49, 153-163.	2.0	29
331	P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. Journal of Neurochemistry, 2004, 87, 1010-1023.	2.1	95
332	Linkage Disequilibrium and Haplotype Architecture for two ABC Transporter Genes (ABCC1 and ABCG2) in Chinese Population: Implications for Pharmacogenomic Association Studies. Annals of Human Genetics, 2004, 68, 563-573.	0.3	30
333	Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance. Drug Development Research, 2004, 62, 254-272.	1.4	4
334	Drug ADME-associated protein database as a resource for facilitating pharmacogenomics research. Drug Development Research, 2004, 62, 134-142.	1.4	15

#	Article	IF	Citations
335	Enhancedin vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. International Journal of Cancer, 2004, 111, 484-493.	2.3	35
336	Do Multidrug Resistanceâ€Associated Proteinâ€1 and â€2 Play Any Role in the Elimination of Estradiolâ€17Î²â€Glucuronide and 2,4â€Dinitrophenylâ€Sâ€Glutathione Across the Bloodâ€“Cerebrospinal Fluid Barrier?. Journal of Pharmaceutical Sciences, 2004, 93, 99-107.	1.6	36
337	The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. International Journal of Pharmaceutics, 2004, 273, 135-147.	2.6	10
338	Multidrug-resistant hela cells overexpressing MRP1 exhibit sensitivity to cell killing by hyperthermia: Interactions with etoposide. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1538-1551.	0.4	26
339	Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Research, 2004, 58, 85-91.	0.8	89
340	Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Research, 2004, 58, 53-66.	0.8	57
341	Predicting drug response based on gene expression. Critical Reviews in Oncology/Hematology, 2004, 51, 205-227.	2.0	15
342	Expression of Multiple Drug Resistance Conferring Proteins in Normal Chinese and Caucasian Small and Large Intestinal Tissue Samples. Molecular Pharmaceutics, 2004, 1, 447-454.	2.3	11
343	Ionophoric Activity of Pluronic Block Copolymersâ€. Biochemistry, 2004, 43, 3696-3703.	1.2	50
344	Mechanisms of cancer: multidrug resistance. Drug Discovery Today Disease Mechanisms, 2004, 1, 229-234.	0.8	62
345	MÃ©canismes de rÃ©sistance aux agents cytostatiques. EMC - Hematologie, 2004, 1, 59-68.	0.1	0
346	Tacrolimus reduces urinary excretion of leukotriene E4 and inhibits aspirin-induced asthma to threshold dose of aspirin. Journal of Allergy and Clinical Immunology, 2004, 114, 1278-1281.	1.5	22
347	Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. Canadian Journal of Physiology and Pharmacology, 2004, 82, 1084-1090.	0.7	27
348	Response of rat alveolar type II cells and human lung tumor cells towards oxidative stress induced by hydrogen peroxide and paraquat. Toxicology Letters, 2004, 151, 69-78.	0.4	11
349	Pharmacogenetics of neoplastic diseases: new trends. Pharmacological Research, 2004, 49, 331-342.	3.1	21
350	Drug Transfer and Metabolism by the Human Placenta. Clinical Pharmacokinetics, 2004, 43, 487-514.	1.6	501
351	Genetic Predictors of the Clinical Response to Opioid Analgesics. Clinical Pharmacokinetics, 2004, 43, 983-1013.	1.6	230
352	Glutathione, Altruistic Metabolite in Fungi. Advances in Microbial Physiology, 2004, 49, 1-76.	1.0	241

#	Article	IF	Citations
353	Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics, 2004, 5, 559-569.	0.6	38
354	Radiopharmaceuticals for Assessment of Multidrug Resistance P-Glycoprotein-Mediated Drug Transport Activity. Bioconjugate Chemistry, 2004, 15, 1464-1474.	1.8	58
355	The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance. Drug Metabolism Reviews, 2004, 36, 669-701.	1.5	114
356	Regulation of transcription of the human MRP7 gene. Gene, 2004, 341, 129-139.	1.0	17
357	Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Letters, 2004, 205, 107-115.	3.2	13
358	Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Letters, 2004, 569, 1-6.	1.3	96
359	Molecular mechanisms of platinum resistance: still searching for the Achilles? heel. Drug Resistance Updates, 2004, 7, 227-232.	6.5	96
360	The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal bloodâ€“testis barrier and in primary testicular tumours. European Journal of Cancer, 2004, 40, 2064-2070.	1.3	155
361	Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression. Biochemical and Biophysical Research Communications, 2004, 324, 937-945.	1.0	44
362	Activation of multidrug efflux transporter activity at fertilization in sea urchin embryos (Strongylocentrotus purpuratus). Developmental Biology, 2004, 276, 452-462.	0.9	83
363	Molecular aspects of medicine: from experimental to clinical hepatology. Molecular Aspects of Medicine, 2004, 25, 221-360.	2.7	55
364	Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1). Journal of Biological Chemistry, 2004, 279, 38871-38880.	1.6	41
365	Transmembrane Helix 11 of Multidrug Resistance Protein 1 (MRP1/ABCC1):â€‰ Identification of Polar Amino Acids Important for Substrate Specificity and Binding of ATP at Nucleotide Binding Domain 1. Biochemistry, 2004, 43, 9413-9425.	1.2	30
366	Herbal Modulation of Pâ€Glycoprotein. Drug Metabolism Reviews, 2004, 36, 57-104.	1.5	355
367	Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, 353-365.	0.6	13
368	Predicting drug sensitivity and resistance. Cancer Cell, 2004, 6, 129-137.	7.7	496
369	Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Oncology Reports, 2004, 12, 1365.	1.2	5
370	Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl. Journal of Clinical Pharmacology, 2004, 44, 224-233.	1.0	72

#	Article	IF	Citations
371	Pharmacogenomics of MDR and MRP subfamilies. Personalized Medicine, 2004, 1, 85-104.	0.8	19
372	Predicting drug response based on gene expression. Critical Reviews in Oncology/Hematology, 2004, 51, 205-227.	2.0	32
373	Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncology Reports, 2004, 12, 955.	1.2	59
374	Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics and Genomics, 2004, 14, 155-164.	5.7	113
375	Basic mechanisms of partial epilepsies. Current Opinion in Neurology, 2004, 17, 155-159.	1.8	26
377	Biology of a Novel Organic Solute and Steroid Transporter, OSTÎ‘-OSTÎ². Experimental Biology and Medicine, 2005, 230, 689-698.	1.1	46
378	Role of Lymphocyte Multidrug Resistance Protein 1 in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 257-266.	0.9	16
379	Enhancement of brain distribution of anticancer agents using Î”G, the 12kDa active fragment of ZOT. International Journal of Pharmaceutics, 2005, 306, 122-131.	2.6	20
380	Endogenous thiols and MRP transporters contribute to Hg2+ efflux in HgCl2-treated tubular MDCK cells. Toxicology, 2005, 206, 137-151.	2.0	43
381	P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines. Cell Biology International, 2005, 29, 269-275.	1.4	10
382	Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics, 2005, 77, 291-301.	2.3	138
383	Influence of functional haplotypes in the drug transporter gene on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 182-190.	2.3	64
384	Overview of Tumor Cell Chemoresistance Mechanisms. , 2005, 111, 127-148.		109
385	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics, 2005, 6, 115-138.	0.6	114
386	EVOLUTION OF THE ATP-BINDING CASSETTE (ABC) TRANSPORTER SUPERFAMILY IN VERTEBRATES. Annual Review of Genomics and Human Genetics, 2005, 6, 123-142.	2.5	540
387	Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology, 2005, 46, 389-395.	1.6	15
388	Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. British Journal of Haematology, 2005, 131, 457-467.	1.2	34
389	Gender-specific expression of liver organic anion transporters in rat. European Journal of Clinical Investigation, 2005, 35, 635-643.	1.7	47

#	Article	IF	Citations
390	Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience, 2005, 6, 591-602.	4.9	804
391	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. British Journal of Cancer, 2005, 93, 89-97.	2.9	50
392	Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. Epilepsia, 2005, 46, 224-235.	2.6	269
393	CAR and PXR: Xenosensors of endocrine disrupters?. Chemico-Biological Interactions, 2005, 155, 111-128.	1.7	246
394	Endogenous expression of liver-specific drug transporters for organic anions in the rat hepatocytoma fusion cell line HPCT-1E3. European Journal of Cell Biology, 2005, 84, 677-686.	1.6	13
395	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology, 2005, 527, 1-22.	1.7	32
396	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. European Journal of Pharmaceutical Sciences, 2005, 24, 513-524.	1.9	29
397	Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochemical Pharmacology, 2005, 69, 123-132.	2.0	10
398	Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochemical Pharmacology, 2005, 69, 415-423.	2.0	35
399	Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochemical Pharmacology, 2005, 69, 699-708.	2.0	168
400	Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochemical Pharmacology, 2005, 70, 640-647.	2.0	32
401	Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicology and Applied Pharmacology, 2005, 204, 238-255.	1.3	223
402	Cancer cell adaptation to chemotherapy. BMC Cancer, 2005, 5, 78.	1.1	110
403	Differentiation and drug resistance relationships in leukemia cells. Journal of Cellular Biochemistry, 2005, 94, 98-108.	1.2	10
404	Differential effect of insulin and elevated glucose level on adenosine handling in rat T lymphocytes. Journal of Cellular Biochemistry, 2005, 96, 1296-1310.	1.2	11
405	Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. International Journal of Cancer, 2005, 115, 155-163.	2.3	26
406	Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. International Journal of Cancer, 2005, 115, 359-367.	2.3	165
407	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104, 682-691.	2.0	267

#	Article	IF	Citations
408	Multidrug resistance proteins (MRPs) and implication in drug development. Drug Development Research, 2005, 64, 1-18.	1.4	29
409	Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Medicinal Research Reviews, 2005, 25, 453-472.	5.0	133
410	EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemotherapy and Pharmacology, 2005, 55, 461-465.	1.1	32
411	Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemotherapy and Pharmacology, 2005, 56, 344-350.	1.1	67
412	Expression of lung resistance-related protein, LRP, and multidrug resistance-related protein, MRP1, in normal human lung cells in long-term cultures. Archives of Toxicology, 2005, 79, 600-609.	1.9	10
413	A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCICâ€“CTG) IND 130. Investigational New Drugs, 2005, 23, 445-453.	1.2	6
414	A Fluorometric Screening Assay for Drug Efflux Transporter Activity in the Blood-Brain Barrier. Pharmaceutical Research, 2005, 22, 113-121.	1.7	22
415	Role of Intestinal First-Pass Metabolism of Baicalein in its Absorption Process. Pharmaceutical Research, 2005, 22, 1050-1058.	1.7	121
416	Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport. Pharmaceutical Research, 2005, 22, 1559-1577.	1.7	156
417	Pharmacokinetics of Dietary Phenethyl Isothiocyanate in Rats. Pharmaceutical Research, 2005, 22, 1658-1666.	1.7	96
418	Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. Pharmaceutical Research, 2005, 22, 1837-1853.	1.7	127
419	Quantitative Structureâ€“Activity Relationship and Quantitative Structureâ€“Pharmacokinetics Relationship of 1,4-Dihydropyridines and Pyridines as Multidrug Resistance Modulators. Pharmaceutical Research, 2005, 22, 1989-1996.	1.7	20
420	Imaging Multidrug Resistance P-glycoprotein Transport Function Using MicroPET with Technetium-94m-Sestamibi. Molecular Imaging, 2005, 4, 153535002005041.	0.7	22
421	Expression and function of multidrug resistance transporters at the bloodâ€“brain barriers. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 233-246.	1.5	47
422	EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES. Drug Metabolism and Disposition, 2005, 33, 1220-1228.	1.7	60
423	Polyspecific Organic Cation Transport: Insights into the Substrate Binding Site. Molecular Pharmacology, 2005, 67, 1391-1392.	1.0	6
424	Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interactions. Current Drug Metabolism, 2005, 6, 455-468.	0.7	100
425	Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. American Journal of Physiology - Renal Physiology, 2005, 288, F327-F333.	1.3	201

#	Article	IF	Citations
426	Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon Tetrachloride. Toxicological Sciences, 2005, 83, 44-52.	1.4	110
427	Expression of Multidrug Resistanceâ€“Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2005, 11, 8661-8668.	3.2	103
429	Inhibitory Activity of a Green Tea Extract and some of its Constituents on Multidrug Resistance-Associated Protein 2 Functionality. Planta Medica, 2005, 71, 135-141.	0.7	25
430	Biliary Transport Systems: Shortâ€Term Regulation. Methods in Enzymology, 2005, 400, 542-557.	0.4	23
431	Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 219-232.	1.5	15
433	Chemopreventive Effects of Aloe Against Genotoxicity Induced by Benzo[a]pyrene. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2005, 68, 1841-1860.	1.1	9
434	P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1249-1256.	1.3	76
436	Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy. Journal of Clinical Oncology, 2005, 23, 205-229.	0.8	148
437	Acceleration of Glutathione Efflux and Inhibition of Î³-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity. Journal of Biological Chemistry, 2005, 280, 6950-6959.	1.6	82
438	Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology, 2005, 23, 1161-1168.	0.8	97
439	VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION. Drug Metabolism and Disposition, 2005, 33, 896-904.	1.7	144
440	Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat Hepatocytes. Molecular Pharmacology, 2005, 67, 1334-1341.	1.0	67
441	Molecular diagnosis of ATP-binding cassette transporter-related diseases. Expert Review of Molecular Diagnostics, 2005, 5, 755-767.	1.5	11
442	Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 564-568.	0.5	18
443	Cyclooxygenase-independent down-regulation of multidrug resistanceâ€“associated protein-1 expression by celecoxib in human lung cancer cells. Molecular Cancer Therapeutics, 2005, 4, 1358-1363.	1.9	63
444	Long Term Azithromycin in Cystic Fibrosis: Another Possible Mechanism of Action?. Journal of Chemotherapy, 2005, 17, 393-400.	0.7	20
445	Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. International Journal of Oncology, 2005, 26, 247.	1.4	8
446	The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates. Cancer Research, 2005, 65, 4425-4430.	0.4	114

#	Article	IF	Citations
448	Uptake and Efflux Transporters for Conjugates in Human Hepatocytes. Methods in Enzymology, 2005, 400, 531-542.	0.4	39
449	N-Linked Glycosylation of the Human ABC Transporter ABCG2 on Asparagine 596 Is Not Essential for Expression, Transport Activity, or Trafficking to the Plasma Membrane. Biochemistry, 2005, 44, 5420-5429.	1.2	108
450	Zidovudine plus sulfamethoxazoleâ€“trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. International Immunopharmacology, 2005, 5, 1881-1894.	1.7	4
451	Patients with premature coronary artery disease who carry the ABCC6 R1141X mutation have no Pseudoxanthoma Elasticum phenotype. International Journal of Cardiology, 2005, 100, 389-393.	0.8	20
452	Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1733, 29-52.	1.2	130
453	Pemetrexed: A multitargeted antifolate. Clinical Therapeutics, 2005, 27, 1343-1382.	1.1	114
454	Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: Current views and new therapeutic prospects. Cancer Treatment Reviews, 2005, 31, 361-379.	3.4	23
455	Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomedicine and Pharmacotherapy, 2005, 59, 104-114.	2.5	73
456	Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. Cancer Letters, 2005, 217, 181-190.	3.2	18
457	The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Letters, 2005, 228, 241-246.	3.2	30
458	Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology, 2005, 76, 22-76.	2.8	544
459	Should chloroquine be laid to rest?. Acta Tropica, 2005, 96, 16-23.	0.9	41
460	ATP-binding cassette (ABC) transporters in normal and pathological lung. Respiratory Research, 2005, 6, 59.	1.4	167
461	ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Molecular Cancer, 2005, 4, 18.	7.9	147
462	Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Molecular Cancer, 2005, 4, 25.	7.9	117
463	Characterization of the humanMDR1 gene. AAPS Journal, 2005, 7, E1-E5.	2.2	78
464	Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx, 2005, 2, 86-98.	6.0	715
465	Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application. Cancer Investigation, 2005, 23, 443-464.	0.6	61

#	Article	IF	Citations
466	Mechanisms of Drug Resistance in Cancer Chemotherapy. Medical Principles and Practice, 2005, 14, 35-48.	1.1	500
467	The Genetics of ATPâ€Binding Cassette Transporters. Methods in Enzymology, 2005, 400, 409-429.	0.4	142
468	Modulation of MRP-1-Mediated Multidrug Resistance by Indomethacin Analogues. Journal of Medicinal Chemistry, 2005, 48, 1179-1187.	2.9	42
469	Drug Delivery to the Eye. Advances in Organ Biology, 2005, 10, 307-351.	0.1	27
470	Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica, 2005, 35, 877-890.	0.5	56
471	Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer. American Journal of Cancer, 2006, 5, 285-297.	0.4	12
472	Cancer Drug Resistance. , 2006, , .		21
473	Advances in strategies to improve drug delivery to brain tumors. Expert Review of Neurotherapeutics, 2006, 6, 1495-1509.	1.4	57
474	Elevated Reactive Oxygen Species but not Glutathione Regulate Mercury Resistance to AML-2/DX100 Cells. Immunopharmacology and Immunotoxicology, 2006, 28, 545-555.	1.1	6
475	CYP3A4 and MDR Mediated Interactions in Drug Therapy. Clinical Research and Regulatory Affairs, 2006, 23, 125-163.	2.1	7
476	Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. International Journal of Toxicology, 2006, 25, 231-259.	0.6	353
477	ExpresiÃ³n de proteÃnas relacionadas con resistencia a MÃºltiples Drogas (MDR-ProteÃnas) y resistencia a la quimioterapia en el cÃ¡ncer de pulmÃ³n.. Gaceta Medica De Bilbao, 2006, 103, 105-117.	0.0	0
478	Refractory Factors in Head and Neck Cancer: ATP Binding Cassette Transporters Expressed in Head and Neck Cancer Cell Lines. Oral Science International, 2006, 3, 72-83.	0.3	1
479	ExpresiÃ³n de ProteÃnas Relacionadas con Resistencia a MÃºltiples Drogas (MDR-ProteÃnas) en tumores sÃ³lidos. Gaceta Medica De Bilbao, 2006, 103, 163-175.	0.0	0
480	Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: Chemoresistance and prediction of response to drug therapy. Journal of the Royal College of Surgeons of Edinburgh, 2006, 4, 211-219.	0.8	24
481	IMPROVING THE EFFICACY AND SAFETY OF ANTICANCER AGENTS â€" THE ROLE OF PHARMACOGENETICS. , 2006, , 285-298.		0
482	Glutathione in Cancer Biology and Therapy. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 143-181.	2.7	860
483	Computational Models for Identifying Potential P-Glycoprotein Substrates and Inhibitors. Molecular Pharmaceutics, 2006, 3, 33-44.	2.3	106

#	Article	IF	Citations
484	Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 651-674.	1.5	52
485	Single Photon Emission Computed Tomography and Positron EmissionÂTomography Imaging ofÂMulti-drug Resistant P-glycoproteinâ€"Monitoring a Transport Activity Important inÂCancer, Bloodâ€"Brain Barrier Function and Alzheimer's Disease. Neuroimaging Clinics of North America, 2006, 16, 575-589.	0.5	21
486	Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 351-366.	1.5	187
487	On the putative co-transport of drugs by multidrug resistance proteins. FEBS Letters, 2006, 580, 1085-1093.	1.3	62
488	Flavonoid-mediated inhibition ofÂintestinal ABC transporters may affect theÂoral bioavailability ofÂdrugs, food-borne toxic compounds andÂbioactive ingredients. Biomedicine and Pharmacotherapy, 2006, 60, 508-519.	2.5	143
489	The ATP-binding cassette transporter ABCA2 asÂaÂmediator ofÂintracellular trafficking. Biomedicine and Pharmacotherapy, 2006, 60, 587-592.	2.5	35
490	Role of pharmacogenetics in irinotecan therapy. Cancer Letters, 2006, 234, 90-106.	3.2	96
491	In vitro antileukaemic activity of extracts from berry plant leaves against sensitive and multidrug resistant HL60 cells. Cancer Letters, 2006, 236, 282-291.	3.2	66
492	Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Letters, 2006, 234, 40-50.	3.2	37
493	Flavonoidâ€"drug interactions: Effects of flavonoids on ABC transporters. Life Sciences, 2006, 78, 2116-2130.	2.0	226
494	MDR- and CYP3A4-mediated drugâ€"herbal interactions. Life Sciences, 2006, 78, 2131-2145.	2.0	220
495	In vivo and in vitro modulation of MDR molecules in murine thymocytes. International Immunopharmacology, 2006, 6, 204-215.	1.7	13
496	Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Review of Anticancer Therapy, 2006, 6, 1075-1085.	1.1	334
497	Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends in Pharmacological Sciences, 2006, 27, 17-24.	4.0	292
498	Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers. Journal of Applied Physiology, 2006, 100, 1392-1399.	1.2	59
499	Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. International Journal of Oncology, 2006, 28, 237.	1.4	13
500	Interaction of Drug Transporters with Excipients. , 0, , 1-31.		3
501	Molecular features linked to the growth-inhibitory effects of gemcitabine on human pancreatic cancer cells. Oncology Reports, 2006, 16, 1285.	1.2	5

#	Article	IF	Citations
502	Regulation of mRNA Expression of MDR1, MRP1, MRP2 and MRP3 by Prototypical Microsomal Enzyme Inducers in Primary Cultures of Human and Rat Hepatocytes. Drug Metabolism and Pharmacokinetics, 2006, 21, 297-307.	1.1	35
503	Ethnic Differences in Pharmacogenetically Relevant Genes. Current Drug Targets, 2006, 7, 1641-1648.	1.0	66
504	Mitochondrial Oxidative Stress in the Lungs of Cystic Fibrosis Transmembrane Conductance Regulator Protein Mutant Mice. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 579-586.	1.4	78
506	Multidrug Transporters as Drug Targets. Current Drug Targets, 2006, 7, 911-921.	1.0	53
507	Delivery of Protein and Peptide Drugs to Brain Tumors. , 2006, , 309-334.		1
508	The GCC repeat length in the 5'UTR of MRP1 gene is polymorphic: a functional characterization of its relevance for cystic fibrosis. BMC Medical Genetics, 2006, 7, 7.	2.1	6
509	Proteomic analysis of pulmonary sclerosing hemangioma. Proteomics, 2006, 6, 4877-4883.	1.3	11
510	PHARMACOGENETICS APPROACH TO THERAPEUTICS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 525-532.	0.9	25
511	Increase in multidrug transport activity is associated with oocyte maturation in sea stars. Development Growth and Differentiation, 2006, 48, 559-573.	0.6	26
512	Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Science, 2006, 97, 1260-1266.	1.7	39
513	Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 2006, 5, 219-234.	21.5	3,098
514	Gene therapy with drug resistance genes. Cancer Gene Therapy, 2006, 13, 335-345.	2.2	23
515	HIV-TAT Protein Upregulates Expression of Multidrug Resistance Protein 1 in the Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 1052-1065.	2.4	88
516	Design and synthesis of novel amino-substituted xanthenones and benzo[b]xanthenones: Evaluation of their antiproliferative activity and their ability to overcome multidrug resistance toward MES-SA/DÃ—5 cells. Bioorganic and Medicinal Chemistry, 2006, 14, 2910-2934.	1.4	13
517	Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Research, 2006, 68, 213-228.	0.8	120
518	Expression of the multidrug transporter MRP2 in the bloodâ€“brain barrier after pilocarpine-induced seizures in rats. Epilepsy Research, 2006, 69, 1-14.	0.8	55
519	Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Epilepsy Research, 2006, 71, 76-87.	0.8	37
520	Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. International Journal of Pharmaceutics, 2006, 313, 144-149.	2.6	152

#	Article	IF	Citations
521	Involvement of NF-Î¹B and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells. Leukemia Research, 2006, 30, 145-152.	0.4	17
522	ABC drug transporter at the bloodâ€“brain barrier. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 294-298.	1.8	24
523	Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemotherapy and Pharmacology, 2006, 57, 376-388.	1.1	100
524	Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemotherapy and Pharmacology, 2006, 58, 1-12.	1.1	38
525	Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemotherapy and Pharmacology, 2006, 59, 61-69.	1.1	23
526	Non-destructive micromethod for MRP1 functional assay in human lung tumor cells. Archives of Toxicology, 2006, 80, 125-133.	1.9	10
527	MDR- and CYP3A4-Mediated Drugâ€“Drug Interactions. Journal of NeuroImmune Pharmacology, 2006, 1, 323-339.	2.1	159
528	The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines. Archives of Pharmacal Research, 2006, 29, 1018-1023.	2.7	18
531	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 2006, 100, 239-246.	0.6	58
532	The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chemico-Biological Interactions, 2006, 159, 90-103.	1.7	43
533	Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance. Chemico-Biological Interactions, 2006, 160, 217-224.	1.7	26
534	Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells. European Journal of Pharmaceutical Sciences, 2006, 28, 291-299.	1.9	171
535	Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochemical Pharmacology, 2006, 71, 1695-1704.	2.0	65
536	Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1Î±. Biochemical Pharmacology, 2006, 72, 512-522.	2.0	94
537	Expression and function of efflux drug transporters in the intestine. , 2006, 109, 137-161.		311
538	Low expression ofMRP1/GS-X pump ATPase in lymphocytes of Walker 256 tumour-bearing rats is associated with cyclopentenone prostaglandin accumulation and cancer immunodeficiency. Cell Biochemistry and Function, 2006, 24, 23-39.	1.4	27
539	Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer, 2006, 106, 1217-1226.	2.0	68
540	Hepatobiliary transporters and drug-induced cholestasis. Hepatology, 2006, 44, 778-787.	3.6	260

#	Article	IF	Citations
541	In vitro andin vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. International Journal of Cancer, 2006, 119, 414-422.	2.3	67
542	Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant ofO6-methylguanine-DNA-methyl transferase. Journal of Gene Medicine, 2006, 8, 972-979.	1.4	11
543	Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. International Journal of Oncology, 2006, 29, 225-35.	1.4	39
544	Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells. International Journal of Oncology, 2006, 29, 397.	1.4	15
545	Pharmacological Strategies for Overcoming Multidrug Resistance. Current Drug Targets, 2006, 7, 861-879.	1.0	335
546	Correlates of imexon sensitivity in human multiple myeloma cell lines. Leukemia and Lymphoma, 2006, 47, 97-109.	0.6	15
547	Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4. Current Drug Metabolism, 2006, 7, 105-118.	0.7	75
548	Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 1546-1553.	0.8	155
549	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 331-344.	0.3	5
550	Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting. Current Pharmaceutical Design, 2006, 12, 2833-2848.	0.9	25
551	Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines. Current Cancer Drug Targets, 2006, 6, 295-311.	0.8	79
552	Chapter 6.4 Microdialysis as a method to study blood-brain barrier transport mechanisms. Handbook of Behavioral Neuroscience, 2006, , 545-572.	0.7	1
554	Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology, 2006, 24, 4228-4235.	0.8	31
555	Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation. Journal of Immunology, 2006, 176, 5191-5198.	0.4	56
556	Treatment of germ cell tumors â€“ update 2006. Annals of Oncology, 2006, 17, x31-x35.	0.6	6
557	Human T cell cytokine responses are dependent on multidrug resistance protein-1. International Immunology, 2006, 18, 485-493.	1.8	25
558	Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux. Molecular Pharmacology, 2006, 69, 1499-1505.	1.0	96
559	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. Clinical Microbiology Reviews, 2006, 19, 763-787.	5.7	35

#	Article	IF	Citations
560	Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 87-103.	0.3	0
561	Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System. Pharmacological Reviews, 2006, 58, 140-161.	7.1	275
562	Human ABC Transporter ABCG2 in Xenobiotic Protection and Redox Biology. Drug Metabolism Reviews, 2006, 38, 371-391.	1.5	62
563	Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiological Reviews, 2006, 86, 849-899.	13.1	679
564	Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 2006, 129, 18-35.	3.7	350
565	Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Molecular Cancer Therapeutics, 2007, 6, 1641-1649.	1.9	342
566	Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor Î±-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study. Drug Metabolism and Disposition, 2007, 35, 835-840.	1.7	11
567	Vitamin E Analogs, a Novel Group of â€œMitocans,â€•as Anticancer Agents: The Importance of Being Redox-Silent. Molecular Pharmacology, 2007, 71, 1185-1199.	1.0	131
568	The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds. Current Drug Metabolism, 2007, 8, 47-57.	0.7	43
569	Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology, 2007, 18, 1293-1306.	0.6	55
570	Metabolism of Dietary Polyphenols and Possible Interactions with Drugs. Current Drug Metabolism, 2007, 8, 499-507.	0.7	72
571	Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of Salvia miltiorrhiza Bunge. Current Drug Metabolism, 2007, 8, 325-340.	0.7	74
572	Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 280-291.	0.3	0
573	Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs. Current Drug Metabolism, 2007, 8, 787-802.	0.7	60
574	Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity. Current Cancer Drug Targets, 2007, 7, 504-509.	0.8	26
575	Endothelin and calciotropic hormones share regulatory pathways in multidrug resistance protein 2-mediated transport. American Journal of Physiology - Renal Physiology, 2007, 292, F38-F46.	1.3	13
576	The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncology Reports, 2007, 18, 893.	1.2	12
577	Prediction of Chemosensitivity Using Multigene Analysis in Head and Neck Squamous Cell Carcinoma. Oncology, 2007, 73, 104-111.	0.9	14

#	Article	IF	Citations
578	Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. Cell Cycle, 2007, 6, 2001-2004.	1.3	14
579	Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2007, 35, 1970-1978.	1.7	84
580	Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, 2007, 12, 511-517.	0.7	33
581	Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 331-343.	1.3	155
582	Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 708-715.	0.6	81
583	Accelerated Urinary Excretion of Methylmercury following Administration of Its Antidote N-Acetylcysteine Requires Mrp2/Abcc2, the Apical Multidrug Resistance-Associated Protein. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 378-384.	1.3	47
584	Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles. Drug Metabolism and Disposition, 2007, 35, 937-945.	1.7	34
585	Altered Protein Expressions in Chronic PCB-153â€“Induced Human Liver (HepG2) Cells. International Journal of Toxicology, 2007, 26, 203-212.	0.6	22
586	Multidrug Resistance Proteins of the ABCC Subfamily. , 0, , 263-318.		7
587	The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. International Journal of Oncology, 2007, , .	1.4	31
588	Therapeutic Drug Monitoring and Clinical Outcomes in Epileptic Egyptian Patients: A Gene Polymorphism Perspective Study. Therapeutic Drug Monitoring, 2007, 29, 305-312.	1.0	73
589	Pharmacokinetics in cancer chemotherapy. European Journal of Cancer, 2007, 43, 271-282.	1.3	27
590	Effect of poly(ethylene glycol)-block-polylactide nanoparticles on hepatic cells of mouse: Low cytotoxicity, but efflux of the nanoparticles by ATP-binding cassette transporters. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 268-280.	2.0	23
591	Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells. Cancer Letters, 2007, 245, 252-262.	3.2	15
592	Functional analysis of the polymorphism â^'211C>T in the regulatory region of the human ABCC3 gene. Life Sciences, 2007, 80, 1490-1494.	2.0	27
593	P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 878-886.	2.5	21
594	Intestinal and Hepatic Glucuronidation of Flavonoids. Molecular Pharmaceutics, 2007, 4, 833-845.	2.3	152
595	Diet/Nutrient Interactions with Drug Transporters. , 0, , 665-708.		3

#	Article	IF	Citations
596	Human MDR1 and MRP1 Recognize Berberine as Their Transport Substrate. Bioscience, Biotechnology and Biochemistry, 2007, 71, 242-245.	0.6	41
597	Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy. CNS Drugs, 2007, 21, 143-164.	2.7	40
598	Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Review of Anticancer Therapy, 2007, 7, 1369-1378.	1.1	94
599	Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma. Clinical Cancer Research, 2007, 13, 427-433.	3.2	185
600	Neuropharmacology of HIV/AIDS. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 319-364.	1.0	0
601	Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 2007, 10, 39-45.	2.0	47
602	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors. Drug Metabolism and Disposition, 2007, 35, 340-344.	1.7	125
603	Human Glutathione S-Transferase-Mediated Glutathione Conjugation of Curcumin and Efflux of These Conjugates in Caco-2 Cells. Chemical Research in Toxicology, 2007, 20, 1895-1902.	1.7	50
604	Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 819-830.	1.5	62
606	The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. Clinical Cancer Research, 2007, 13, 1663-1674.	3.2	601
607	The Role of Efflux Pumps in Drug-Resistant Metastatic Breast Cancer: New Insights and Treatment Strategies. Clinical Breast Cancer, 2007, 7, 749-756.	1.1	57
608	The Biology and Function of Transporters. , 2007, , 51-85.		7
609	Expression of Proteins Associated With Multidrug Resistance to Chemotherapy in Lung Cancer. Archivos De Bronconeumologia, 2007, 43, 479-484.	0.4	9
610	Biological Background. , 2007, , 3-18.		0
611	Passive Permeability and Active Transport Models for the Prediction of Oral Absorption. , 2007, , 259-278.		8
612	Tuftsin Augments Antitumor Efficacy of Liposomized Etoposide against Fibrosarcoma in Swiss Albino Mice. Molecular Medicine, 2007, 13, 266-276.	1.9	26
613	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. Journal of Biochemical and Molecular Toxicology, 2007, 21, 243-251.	1.4	43
614	Cyclosporin a inhibits HTLVâ€‘tax expression and shows antiâ€tumor effects in combination with VPâ€16. Journal of Medical Virology, 2007, 79, 1906-1913.	2.5	6

#	Article	IF	Citations
615	Oxycodone induces overexpression of Pâ€glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. Journal of Pharmaceutical Sciences, 2007, 96, 2494-2506.	1.6	92
616	Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area. Clinical Oncology, 2007, 19, 23-37.	0.6	64
617	Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC). Applied Radiation and Isotopes, 2007, 65, 696-700.	0.7	17
618	Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. International Journal of Pharmaceutics, 2007, 337, 188-193.	2.6	73
619	Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. International Journal of Pharmaceutics, 2007, 339, 139-147.	2.6	94
620	Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theoretical Biology and Medical Modelling, 2007, 4, 33.	2.1	41
621	Modelling of the bloodâ€“brain barrier in drug discovery and development. Nature Reviews Drug Discovery, 2007, 6, 650-661.	21.5	522
622	Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol. Clinical Pharmacology and Therapeutics, 2007, 81, 669-678.	2.3	131
623	Upregulation of Brain Expression of P-Glycoprotein in MRP2-deficient TR-Rats Resembles Seizure-induced Up-regulation of This Drug Efflux Transporter in Normal Rats. Epilepsia, 2007, 48, 631-645.	2.6	37
624	Phosphodiesterase type 2 and the homeostasis of cyclic GMP in living thalamic neurons. Journal of Neurochemistry, 2007, 102, 1875-1886.	2.1	32
626	Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1775, 237-262.	3.3	177
627	Glutathione depletion activates mitogen-activated protein kinase (MAPK) pathways that display organ-specific responses and brain protection in mice. Free Radical Biology and Medicine, 2007, 43, 1335-1347.	1.3	72
628	Mechanistic study on the intestinal absorption and disposition of baicalein. European Journal of Pharmaceutical Sciences, 2007, 31, 221-231.	1.9	100
629	Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine, 2007, 14, 381-389.	2.3	37
630	Bloodâ€“brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. Journal of Psychiatric Research, 2007, 41, 179-188.	1.5	82
631	Wogonin, a Plant Flavone, Potentiates Etoposide-Induced Apoptosis in Cancer Cells. Annals of the New York Academy of Sciences, 2007, 1095, 521-526.	1.8	20
632	CURCUMIN AS CHEMOSENSITIZER. Advances in Experimental Medicine and Biology, 2007, 595, 269-300.	0.8	58
633	Intracellular Localization is a Cofactor for the Phototoxicity of Protoporphyrin IX in the Gastrointestinal Tract: In Vitro StudyÂ¶â€. Photochemistry and Photobiology, 2007, 78, 393-399.	1.3	0

#	Article	IF	Citations
634	Understanding cisplatin resistance using cellular models. IUBMB Life, 2007, 59, 696-699.	1.5	143
635	Availability and applications of ATP-binding cassette (ABC) transporter blockers. Applied Microbiology and Biotechnology, 2007, 76, 279-286.	1.7	47
636	Multidrug Resistance Protein 1 (MRP1) in Rabbit Conjunctival Epithelial Cells: Its Effect on Drug Efflux and Its Regulation by Adenoviral Infection. Pharmaceutical Research, 2007, 24, 1490-1500.	1.7	23
637	A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer and Metastasis Reviews, 2007, 26, 15-37.	2.7	59
638	Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Archiv European Journal of Physiology, 2007, 453, 661-673.	1.3	256
639	Metalloprobes: Synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells. Journal of Inorganic Biochemistry, 2007, 101, 1347-1353.	1.5	18
640	Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 159-164.	0.6	17
641	An overview of cancer multidrug resistance: a still unsolved problem. Cellular and Molecular Life Sciences, 2008, 65, 3145-3167.	2.4	375
642	Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro. Cancer Chemotherapy and Pharmacology, 2008, 62, 117-122.	1.1	1
643	Drug resistance and genetic mapping in PlasmodiumÂfalciparum. Current Genetics, 2008, 54, 223-239.	0.8	56
644	Androgen regulation of multidrug resistanceâ€associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate, 2008, 68, 1421-1429.	1.2	70
645	Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences, 2008, 97, 4696-4740.	1.6	237
646	Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIVâ€1 infection. Glia, 2008, 56, 1711-1735.	2.5	85
647	Development of predictive in silico model for cyclosporine- and aureobasidin-based P-glycoprotein inhibitors employing receptor surface analysis. Journal of Molecular Graphics and Modelling, 2008, 27, 439-451.	1.3	9
648	Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. Journal of Photochemistry and Photobiology B: Biology, 2008, 93, 119-126.	1.7	185
649	A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5). European Journal of Medicinal Chemistry, 2008, 43, 2557-2567.	2.6	26
650	Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells. Bioorganic and Medicinal Chemistry, 2008, 16, 474-487.	1.4	16
651	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 362-373.	1.4	78

#	Article	IF	Citations
652	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorganic and Medicinal Chemistry, 2008, 16, 3732-3743.	1.4	54
653	Structureâ€“activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorganic and Medicinal Chemistry, 2008, 16, 8224-8236.	1.4	82
654	Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3481-3483.	1.0	35
655	Structureâ€“activity relationship studies of permeability modulating peptide AT-1002. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4584-4586.	1.0	15
656	A New Chemosensitivity Test Using a Thermo-Reversible Gelation Polymer for Recurrent Gynecologic Cancer Patients and a Preliminary Study of Mechanisms of Anticancer Drug Resistance. Human Cell, 2008, 18, 171-180.	1.2	6
657	Cisplatin: a review of toxicities and therapeutic applications. Veterinary and Comparative Oncology, 2008, 6, 1-18.	0.8	343
658	Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Science, 2008, 99, 653-658.	1.7	207
659	ABCG2 Q141K polymorphism is associated with chemotherapyâ€induced diarrhea in patients with diffuse large Bâ€cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone chemotherapy. Cancer Science, 2008, 99, 2496-2501.	1.7	33
660	Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. European Journal of Clinical Investigation, 2008, 38, 134-142.	1.7	33
662	Taxanes, microtubules and chemoresistant breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 96-132.	3.3	313
663	Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. Seminars in Oncology, 2008, 35, S1-S14.	0.8	75
664	Recent progress in tumor pH targeting nanotechnology. Journal of Controlled Release, 2008, 132, 164-170.	4.8	784
665	Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery, 2008, 143, 769-777.	1.0	94
666	Genetic polymorphisms and the fate of the transplanted organ. Transplantation Reviews, 2008, 22, 131-140.	1.2	41
667	The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PKâ€“PD experiments. Journal of Pharmacological and Toxicological Methods, 2008, 57, 114-130.	0.3	59
669	The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. International Journal of Hyperthermia, 2008, 24, 151-159.	1.1	31
670	MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica, 2008, 38, 833-862.	0.5	111
671	The role of hepatic transporters in drug elimination. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 363-379.	1.5	76

#	Article	IF	Citations
672	Antitumor Agents 260. New Desmosdumotin B Analogues with Improved In Vitro Anticancer Activity. Journal of Medicinal Chemistry, 2008, 51, 3297-3303.	2.9	28
673	Basic Research in Pulmonology. Archivos De Bronconeumologia, 2008, 44, 621-628.	0.4	6
674	Advanced Dihydropyridines as Novel Multidrug Resistance Modifiers and Reversing Agents. Topics in Heterocyclic Chemistry, 2007, , 201-252.	0.2	13
675	Renal handling of drugs and xenobiotics. , 2008, , 43-71.		2
676	Chapter 4 Molecular Mechanisms of Adaptation to Folate Deficiency. Vitamins and Hormones, 2008, 79, 99-143.	0.7	48
677	Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, 2008, 448, v-vii.	0.4	8
678	The adjuvant effects of Antrodia Camphorata extracts combined with anti-tumor agents on multidrug resistant human hepatoma cells. Journal of Ethnopharmacology, 2008, 118, 387-395.	2.0	39
680	Effects of cadmium exposure on expression and activity of P-glycoprotein in eastern oysters, Crassostrea virginica Gmelin. Aquatic Toxicology, 2008, 88, 19-28.	1.9	59
681	Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology, 2008, 55, 1364-1375.	2.0	271
682	Role of xenobiotic efflux transporters in resistance to vincristine. Biomedicine and Pharmacotherapy, 2008, 62, 59-64.	2.5	10
683	Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2. Environmental Toxicology and Pharmacology, 2008, 26, 102-108.	2.0	21
684	Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 758-764.	2.0	13
685	Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews, 2008, 34, 378-390.	3.4	288
686	Discovery of a new series of jatrophane and lathyrane diterpenes as potent and specific P-glycoprotein modulators. Organic and Biomolecular Chemistry, 2008, 6, 1756.	1.5	53
687	Prognostic factors in soft-tissue sarcomas: what have we learnt?. Expert Review of Anticancer Therapy, 2008, 8, 139-146.	1.1	7
688	Expression of Multidrug Resistance-Related Proteins p-Glycoproteinglutathione-s-Transferases, Topoisomerase-II and Lung Resistance Protein in Primary Gastric Cardiac Adenocarcinoma. Cancer Investigation, 2008, 26, 344-351.	0.6	35
689	Analysis of the Cryptophycin P450 Epoxidase Reveals Substrate Tolerance and Cooperativity. Journal of the American Chemical Society, 2008, 130, 5492-5498.	6.6	40
690	Drug-Drug Interactions, Second Edition. , 0, , .		8

#	Article	IF	Citations
691	Bioactive Heterocycles VI. Topics in Heterocyclic Chemistry, 2008, , .	0.2	4
692	cGMP Secreted From the Tapeworm Hymenolepis diminuta Is a Signal Molecule to the Host Intestine. Journal of Parasitology, 2008, 94, 771-779.	0.3	7
693	ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	3.2	90
694	Evaluation of the selected barrier properties of retinal pigment epithelial cell line ARPE-19 for an in-vitro blood-brain barrier model. Human and Experimental Toxicology, 2008, 27, 741-749.	1.1	15
695	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer. Cancer Research, 2008, 68, 5380-5389.	0.4	102
696	Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2008, 8, 1207-1222.	1.1	47
697	Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 2603-2616.	0.9	105
698	Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts. Clinical Cancer Research, 2008, 14, 2171-2179.	3.2	106
699	Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport. Drug Metabolism and Disposition, 2008, 36, 1206-1211.	1.7	60
700	CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective. Current Drug Metabolism, 2008, 9, 46-59.	0.7	167
701	Elevated GSH Level Increases Cadmium Resistance through Down-Regulation of Sp1-Dependent Expression of the Cadmium Transporter ZIP8. Molecular Pharmacology, 2008, 74, 823-833.	1.0	43
702	ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opinion on Therapeutic Targets, 2008, 12, 491-504.	1.5	29
704	Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics, 2008, 9, 561-584.	0.6	31
705	Clinical Pharmacogenetics and Potential Application in Personalized Medicine. Current Drug Metabolism, 2008, 9, 738-784.	0.7	196
706	Comparison of Inducibility of Multidrug Resistance (MDR)1, Multidrug Resistance-Associated Protein (MRP)1, and MRP2 mRNAs by Prototypical Microsomal Enzyme Inducers in Primary Cultures of Human and Cynomolgus Monkey Hepatocytes. Biological and Pharmaceutical Bulletin, 2008, 31, 2068-2072.	0.6	17
707	A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood, 2008, 112, 2353-2359.	0.6	48
708	Drug Resistance Molecules: Lessons from Oncology. Novartis Foundation Symposium, 2008, , 19-37.	1.2	14
709	Pharmacogenomics and Personalized Use of Drugs. Current Topics in Medicinal Chemistry, 2008, 8, 1573-1579.	1.0	64

#	Article	IF	Citations
710	Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 220-226.	0.8	19
711	Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development. Current Drug Metabolism, 2008, 9, 419-438.	0.7	65
712	OC144-093, a Novel P glycoprotein Inhibitor for the Enhancement of Anti-Epileptic Therapy. Novartis Foundation Symposium, 2008, , 213-230.	1.2	16
713	Resistance mechanisms to cancer chemotherapy. Frontiers in Bioscience - Landmark, 2008, Volume, 5138.	3.0	131
716	SÃndromes mielodisplÃ¡sicas: aspectos moleculares, laboratoriais e a classificaÃ§Ã£o OMS 2008. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 463-470.	0.7	2
717	OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Frontiers in Bioscience - Landmark, 2009, Volume, 2829.	3.0	90
718	Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione. Journal of Biological Chemistry, 2009, 284, 7687-7696.	1.6	122
719	Expression Levels of Insulin-Like Growth Factor-1 and Multidrug Resistance-Associated Protein-1 Indicate Poor Prognosis in Patients with Gastric Cancer. Digestion, 2009, 80, 148-158.	1.2	44
720	Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents. Journal of Chemotherapy, 2009, 21, 542-549.	0.7	13
721	Strategies to Improve the Efficacy of Platinum Compounds. Current Medicinal Chemistry, 2009, 16, 2355-2365.	1.2	54
722	ABC Transporters as Potential Targets for Modulation of Drug Resistance. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1102-1112.	1.1	42
723	Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L30-L36.	1.3	17
724	The Reversal of Drug-Resistance in Tumors Using a Drug-Carrying Nanoparticular System. International Journal of Molecular Sciences, 2009, 10, 3776-3792.	1.8	42
725	Role of multidrug transporters in neurotherapeutics. Annals of Indian Academy of Neurology, 2009, 12, 89.	0.2	12
726	Physiological and Pharmacological Significance of Glutathione-Conjugate Transport. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2009, 12, 540-551.	2.9	27
727	Combination effects of SC144 and cytotoxic anticancer agents. Anti-Cancer Drugs, 2009, 20, 312-320.	0.7	13
728	Proteomics Identification of Azaspiracid Toxin Biomarkers in Blue Mussels, Mytilus edulis. Molecular and Cellular Proteomics, 2009, 8, 1811-1822.	2.5	27
729	RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Reviews in Molecular Medicine, 2009, 11, e15.	1.6	6

#	Article	IF	Citations
730	Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicology and Applied Pharmacology, 2009, 234, 281-292.	1.3	26
731	Expression of ABCâ€Transport Proteins in Canine Mammary Cancer: Consequences for Chemotherapy. Reproduction in Domestic Animals, 2009, 44, 218-223.	0.6	26
732	Expression of MRP1, BCRP, LRP, and ERCC1 in Advanced Nonâ€“Small-Cell Lung Cancer: Correlation With Response to Chemotherapy and Survival. Clinical Lung Cancer, 2009, 10, 414-421.	1.1	62
733	Hepatitis C virus NS3 protease inhibitors: Large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells. European Journal of Pharmaceutical Sciences, 2009, 38, 556-563.	1.9	14
734	Multiâ€Drugâ€Resistanceâ€Reverting Agents: 2â€Aryloxazole and 2â€Arylthiazole Derivatives as Potent BCRP or MRP1 Inhibitors. ChemMedChem, 2009, 4, 188-195.	1.6	50
735	Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Archives of Gynecology and Obstetrics, 2009, 279, 149-157.	0.8	24
736	Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 114, 195-201.	1.1	83
737	Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein. Pharmaceutical Research, 2009, 26, 914-925.	1.7	77
738	The Antiepileptic Drug Topiramate is a Substrate for Human P-glycoprotein but Not Multidrug Resistance Proteins. Pharmaceutical Research, 2009, 26, 2464-2470.	1.7	44
739	Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clinical and Translational Oncology, 2009, 11, 780-786.	1.2	27
740	Mechanism of drug resistance identified in human lung adenocarcinoma cell line SPC-A1 selected for resistance to docetaxel. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2009, 21, 207-216.	0.7	2
741	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1103-1110.	1.1	57
742	Gene expression associations with the growth inhibitory effects of small molecules on live cells: Specificity of effects and uniformity of mechanisms. Statistical Analysis and Data Mining, 2009, 2, 175-185.	1.4	0
743	Dofequidar fumarate sensitizes cancer stemâ€like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRPâ€mediated drug export. Cancer Science, 2009, 100, 2060-2068.	1.7	73
744	Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity. Leukemia, 2009, 23, 1087-1097.	3.3	15
745	Research in practice: the second barrier of the human skin. JDDG - Journal of the German Society of Dermatology, 2010, 8, 155-158.	0.4	0
746	Inhibition of Pâ€Glycoprotein by Wogonin Is Involved with the Potentiation of Etoposideâ€Induced Apoptosis in Cancer Cells. Annals of the New York Academy of Sciences, 2009, 1171, 132-136.	1.8	38
747	Evaluation of substrate and inhibitor properties of a novel MDR modulator H17 towards transmembrane efflux pumps. European Journal of Medicinal Chemistry, 2009, 44, 3060-3063.	2.6	1

#	Article	IF	Citations
748	Advancement of Structure-Activity Relationship of Multidrug Resistance-Associated Protein 2 Interactions. AAPS Journal, 2009, 11, 406-13.	2.2	13
750	Transportâ"Metabolism Interplay: LXRÎ±-Mediated Induction of Human ABC Transporter ABCC2 (cMOAT/MRP2) in HepG2 Cells. Molecular Pharmaceutics, 2009, 6, 1678-1688.	2.3	3
751	The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treatment Reviews, 2009, 35, 137-147.	3.4	103
752	Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Molecular Aspects of Medicine, 2009, 30, 13-28.	2.7	256
753	Drugâ€"drug interactions of silymarin on the perspective of pharmacokinetics. Journal of Ethnopharmacology, 2009, 121, 185-193.	2.0	153
754	Effects of Ginkgo biloba Extract Ingestion on the Pharmacokinetics of Talinolol in Healthy Chinese Volunteers. Annals of Pharmacotherapy, 2009, 43, 944-949.	0.9	70
755	Dual-Targeting Topotecan Liposomes Modified with Tamoxifen and Wheat Germ Agglutinin Significantly Improve Drug Transport across the Bloodâ"Brain Barrier and Survival of Brain Tumor-Bearing Animals. Molecular Pharmaceutics, 2009, 6, 905-917.	2.3	139
756	Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncology Reports, 2009, 23, .	1.2	31
757	Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Multidrug Resistance by Bivalent Apigenin Homodimers and Their Derivatives. Journal of Medicinal Chemistry, 2009, 52, 5311-5322.	2.9	76
758	Expression of Multidrug Resistance Associated Protein 5 (MRP5) on Cornea and Its Role in Drug Efflux. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 121-132.	0.6	41
760	ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines. Pancreatology, 2009, 9, 136-144.	0.5	75
762	ABC Transporters in Saccharomyces cerevisiae and Their Interactors: New Technology Advances the Biology of the ABCC (MRP) Subfamily. Microbiology and Molecular Biology Reviews, 2009, 73, 577-593.	2.9	161
763	Small-Molecule Multidrug Resistanceâ€"Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Research, 2009, 69, 6573-6580.	0.4	100
764	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	1.6	100
765	Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells. Drug Delivery, 2009, 16, 261-267.	2.5	32
766	Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance. Neoplasia, 2009, 11, 1359-IN11.	2.3	100
767	Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function. Pharmacogenetics and Genomics, 2009, 19, 276-288.	0.7	20
768	Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Anti-Cancer Drugs, 2009, 20, 559-572.	0.7	17

#	Article	IF	Citations
769	Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. International Journal of Oncology, 2009, , .	1.4	22
770	Effect of Methotrexate Treatment on Expression Levels of Organic Anion Transporter Polypeptide 2, P-Glycoprotein and Bile Salt Export Pump in Rats. Biological and Pharmaceutical Bulletin, 2009, 32, 493-496.	0.6	8
771	Membrane Transport Mechanisms of Mizoribine in the Rat Intestine and Human Epithelial LS180 Cells. Biological and Pharmaceutical Bulletin, 2009, 32, 741-745.	0.6	15
772	The Role of ABC Transporters at the Intestinal Barrier. , 0, , 385-409.		0
773	Pharmacogenetics of Drug Metabolizing Enzymes and Transporters: Effects on Pharmacokinetics and Pharmacodynamics of Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 583-592.	0.9	25
774	Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach. Current Pharmaceutical Design, 2010, 16, 2676-2709.	0.9	41
775	Pharmacogenetics of Drug Transporters. Current Pharmaceutical Design, 2010, 16, 220-230.	0.9	93
776	Effects of Dietary Ingredients on Function and Expression of P-Glycoprotein in Human Intestinal Epithelial Cells. Biological and Pharmaceutical Bulletin, 2010, 33, 255-259.	0.6	62
777	Apoptosis induced by doxorubicin and cinchonine in P388 multidrug-resistant cells. Journal of Pharmacy and Pharmacology, 2010, 53, 1029-1039.	1.2	6
778	A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. Journal of Pharmacy and Pharmacology, 2010, 56, 1067-1081.	1.2	28
779	Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. Journal of Pharmacy and Pharmacology, 2010, 57, 1565-1573.	1.2	25
780	The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells. Journal of Pharmacy and Pharmacology, 2010, 60, 647-653.	1.2	4
781	Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2. Molecular Cancer Therapeutics, 2010, 9, 1047-1057.	1.9	26
782	MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 437-446.	1.1	92
783	The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study. Cancer Chemotherapy and Pharmacology, 2010, 66, 159-169.	1.1	9
784	Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine. Cancer Chemotherapy and Pharmacology, 2010, 66, 953-959.	1.1	16
785	Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1477-1488.	1.2	28
786	The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. Journal of Gastroenterology, 2010, 45, 1014-1021.	2.3	94

#	Article	IF	Citations
787	Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. Molecular Biotechnology, 2010, 44, 152-167.	1.3	103
788	Inhibition of cytochrome P450 3A4 activity by schisandrol A and gomisin A isolated from Fructus Schisandrae chinensis. Phytomedicine, 2010, 17, 702-705.	2.3	28
789	The rise of antioxidant signalingâ€"The evolution and hormetic actions of Nrf2. Toxicology and Applied Pharmacology, 2010, 244, 4-15.	1.3	209
790	MRP3: a molecular target for human glioblastoma multiforme immunotherapy.. BMC Cancer, 2010, 10, 468.	1.1	44
791	Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. American Journal of Obstetrics and Gynecology, 2010, 202, 383.e1-383.e7.	0.7	86
792	The stem cell code in oral epithelial tumorigenesis: â€˜The cancer stem cell shift hypothesisâ€™. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 146-162.	3.3	31
793	Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochemical Pharmacology, 2010, 79, 1108-1117.	2.0	93
794	Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochemical Pharmacology, 2010, 79, 1134-1140.	2.0	64
795	Lipid outward translocation by ABC proteins. FEBS Letters, 2010, 584, 2717-2723.	1.3	49
796	Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP). ChemMedChem, 2010, 5, 1498-1505.	1.6	73
797	Alterations of microRNAs and their targets are associated with acquired resistance of MCFâ€7 breast cancer cells to cisplatin. International Journal of Cancer, 2010, 127, 1785-1794.	2.3	301
798	A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: In vitro evaluation. Colloids and Surfaces B: Biointerfaces, 2010, 78, 120-126.	2.5	76
799	Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 180-183.	1.0	25
800	Implications of Anthracycline-Resistant and Taxane-Resistant Metastatic Breast Cancer and New Therapeutic Options. Breast Journal, 2010, 16, 252-263.	0.4	37
801	Vmr 1p is a novel vacuolar multidrug resistance ABC transporter in Saccharomyces cerevisiae. FEMS Yeast Research, 2010, 10, 828-838.	1.1	31
802	Quantitative analysis of cisplatin sensitivity of human esophageal squamous cancer cell lines using inâ€air microâ€PIXE. Cancer Science, 2010, 101, 1487-1492.	1.7	15
803	Role of pharmacogenomics in the drug development. Kathmandu University Medical Journal, 2010, 7, 172-176.	0.1	3
804	Regulation of Hepatobiliary Transporters during Liver Injury. , 2010, , 175-220.		2

#	Article	IF	Citations
805	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 0, , 23.	1.3	40
806	Arsenic-Specific Stem Cell Selection During Malignant Transformation. Journal of the National Cancer Institute, 2010, 102, 638-649.	3.0	85
807	Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis, 2010, 31, 1003-1009.	1.3	46
809	P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions. Drug Metabolism and Drug Interactions, 2010, 25, 3-16.	0.3	17
810	Therapeutic Cancer Vaccines in Combination with Conventional Therapy. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	26
811	CD44⁺CD133⁺population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biology and Therapy, 2010, 10, 1182-1190.	1.5	72
812	Probing Multidrug Resistance P-glycoprotein Transporter Activity with SPECT Radiopharmaceuticals. Current Topics in Medicinal Chemistry, 2010, 10, 1834-1845.	1.0	9
813	Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases. Current Topics in Medicinal Chemistry, 2010, 10, 1732-1756.	1.0	26
814	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metabolism Reviews, 2010, 42, 590-611.	1.5	43
815	Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metabolism Reviews, 2010, 42, 482-538.	1.5	60
816	Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opinion on Drug Delivery, 2010, 7, 1159-1173.	2.4	32
817	An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics. International Journal of Molecular Sciences, 2010, 11, 4826-4842.	1.8	20
818	Cytotoxicity, Hydrophobicity, Uptake, and Distribution of Osmium(II) Anticancer Complexes in Ovarian Cancer Cells. Journal of Medicinal Chemistry, 2010, 53, 840-849.	2.9	120
819	Drug Resistance in Breast Cancer Cells: Biophysical Characterization of and Doxorubicin Interactions with Membrane Lipids. Molecular Pharmaceutics, 2010, 7, 2334-2348.	2.3	112
820	Molecular Mechanism of ATP-Dependent Solute Transport by Multidrug Resistance-Associated Protein 1. Methods in Molecular Biology, 2010, 596, 223-249.	0.4	25
821	Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Letters, 2010, 291, 76-82.	3.2	37
822	Tobacco carcinogen NNK transporter MRP2 regulates CFTR function in lung epithelia: Implications for lung cancer. Cancer Letters, 2010, 292, 246-253.	3.2	28
823	Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010, 399, 91-97.	1.0	10

#	Article	IF	Citations
824	MRP4 knockdown enhances migration, suppresses apoptosis, and produces aggregated morphology in human retinal vascular endothelial cells. Biochemical and Biophysical Research Communications, 2010, 400, 593-598.	1.0	19
825	Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. Journal of Pharmacy and Pharmacology, 2010, 55, 59-66.	1.2	99
826	Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases. Methods in Molecular Biology, 2010, 596, 141-181.	0.4	9
827	Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Research, 2010, 12, S2.	2.2	168
828	The Role of Synthesis and Biosynthetic Logic. , 2010, , 559-579.		0
829	Multidrug resistance in the chronic lymphoproliferative disorders. Leukemia and Lymphoma, 2010, 51, 1793-1804.	0.6	10
830	Exploring the cellular accumulation of metal complexes. Dalton Transactions, 2010, 39, 1159-1170.	1.6	214
831	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochemical Journal, 2011, 439, 141-149.	1.7	63
832	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 192-205.	2.0	61
833	Interaction between Reduced Glutathione and PEOâ^'PPOâ^'PEO Copolymers in Aqueous Solutions: Studied by ¹H NMR and Spinâ^'Lattice Relaxation. Journal of Physical Chemistry B, 2011, 115, 2228-2233.	1.2	13
834	Third-Line Chemotherapy and Novel Agents for Metastatic Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2011, 25, 577-591.	0.9	9
835	ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors Using Recursive Partitioning and Naive Bayesian Classification Techniques. Molecular Pharmaceutics, 2011, 8, 889-900.	2.3	148
836	Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy. Handbook of Experimental Pharmacology, 2011, , 299-323.	0.9	250
838	Drug Transporters. Handbook of Experimental Pharmacology, 2011, , .	0.9	17
839	Chemoenzymatic Synthesis of Cryptophycin Anticancer Agents by an Ester Bond-Forming Non-ribosomal Peptide Synthetase Module. Journal of the American Chemical Society, 2011, 133, 14492-14495.	6.6	37
840	Constitutive mRNA expression and protein activity levels of nine ABC efflux transporters in seven permanent cell lines derived from different tissues of rainbow trout (Oncorhynchus mykiss). Aquatic Toxicology, 2011, 101, 438-446.	1.9	60
841	The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy. Molecular Pharmaceutics, 2011, 8, 1996-2011.	2.3	199
842	Expression and Function of Human MRP1 (ABCC1) Is Dependent on Amino Acids in Cytoplasmic Loop 5 and Its Interface with Nucleotide Binding Domain 2. Journal of Biological Chemistry, 2011, 286, 7202-7213.	1.6	29

#	Article	IF	Citations
843	Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sciences, 2011, 88, 959-971.	2.0	84
844	Investigating the enhancement of cisplatin cytotoxicity on 5637 cells by combination with mogoltacin. Toxicology in Vitro, 2011, 25, 469-474.	1.1	19
845	Glutathione in Cancer Cell Death. Cancers, 2011, 3, 1285-1310.	1.7	247
846	Transporter-Mediated Drugâ€“Drug Interactions with Oral Antidiabetic Drugs. Pharmaceutics, 2011, 3, 680-705.	2.0	29
847	Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens. Melanoma Research, 2011, 21, 206-216.	0.6	9
848	ATP-Binding Cassette Efflux Transporters in Human Placenta. Current Pharmaceutical Biotechnology, 2011, 12, 674-685.	0.9	79
849	Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. Experimental and Therapeutic Medicine, 2011, 2, 783-786.	0.8	11
850	Mechanisms of Resistance to Photodynamic Therapy. Current Medicinal Chemistry, 2011, 18, 2486-2515.	1.2	251
851	PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo. Current Drug Metabolism, 2011, 12, 774-792.	0.7	59
852	Expression of P-gp, MRP, LRP, GST-Ï€ and TopoIIÎ± and intrinsic resistance in human lung cancer cell lines. Oncology Reports, 2011, 26, 1081-9.	1.2	40
853	Feselol Enhances the Cytotoxicity and DNA Damage Induced by Cisplatin in 5637 Cells. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2011, 66, 555-561.	0.6	4
854	Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters. Current Drug Targets, 2011, 12, 621-630.	1.0	199
855	Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells. Oncology Reports, 2011, 27, 232-7.	1.2	7
856	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy, 2011, 5, 117.	2.0	111
857	ATP-binding cassette transporters in primary central nervous system lymphoma: Decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells. Oncology Reports, 2011, 25, 333-9.	1.2	24
858	HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization. International Journal of Oncology, 2011, 38, 807-12.	1.4	38
859	Effect of Genetic Polymorphisms of SLC28A1, ABCG2, and ABCC4 on Bioavailability of Mizoribine in Healthy Japanese Males. Drug Metabolism and Pharmacokinetics, 2011, 26, 538-543.	1.1	22
860	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS Journal, 2011, 278, 3226-3245.	2.2	222

#	Article	IF	Citations
861	Phenotype Prediction of Nonâ€Synonymous Singleâ€Nucleotide Polymorphisms in Human ATPâ€Binding Cassette Transporter Genes. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 94-114.	1.2	15
862	Pseudoxanthoma Elasticum and Sudden Death. Journal of Forensic Sciences, 2011, 56, 418-422.	0.9	17
863	Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. British Journal of Cancer, 2011, 104, 707-713.	2.9	111
864	Investigating the cytotoxic and apoptosis inducing effects of monoterpenoid stylosin in vitro. FÃ¬toterapÁ¬Ã¢, 2011, 82, 742-749.	1.1	29
865	Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice. Biochemical Pharmacology, 2011, 81, 1124-1135.	2.0	37
866	Assessing multidrug resistance protein 1-mediated function in cancer cell multidrug resistance by scanning electrochemical microscopy and flow cytometry. Bioelectrochemistry, 2011, 82, 29-37.	2.4	43
868	5,7-Dimethoxyflavone and Multiple Flavonoids in Combination Alter the ABCG2-Mediated Tissue Distribution of Mitoxantrone in Mice. Pharmaceutical Research, 2011, 28, 1090-1099.	1.7	20
869	Allyl sulfur compounds and cellular detoxification system: effects and perspectives in cancer therapy. Amino Acids, 2011, 41, 103-112.	1.2	52
870	The cytoprotective role of the Keap1â€“Nrf2 pathway. Archives of Toxicology, 2011, 85, 241-272.	1.9	830
871	Pegylated Phosphotidylethanolamine Inhibiting P-Glycoprotein Expression and Enhancing Retention of Doxorubicin in MCF7/ADR Cells. Journal of Pharmaceutical Sciences, 2011, 100, 2267-2277.	1.6	28
872	Accumulation and Photodynamic Activity of Chlorin e6 in Cisplatin-Resistant Human Lung Cancer Cells. Journal of Pharmaceutical Sciences, 2011, 100, 3010-3017.	1.6	11
873	Development of a doubleâ€layer microfluidic chip with flow medium for chemotherapy resistance analysis of lung cancer. Electrophoresis, 2011, 32, 3446-3453.	1.3	6
874	Structureâ€“activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorganic and Medicinal Chemistry, 2011, 19, 2090-2102.	1.4	169
875	Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1). Current Medicinal Chemistry, 2011, 18, 439-481.	1.2	120
876	ABC Proteins Protect the Human Body and Maintain Optimal Health. Bioscience, Biotechnology and Biochemistry, 2011, 75, 401-409.	0.6	71
877	Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil. Drug Metabolism and Disposition, 2011, 39, 132-139.	1.7	54
878	Orange Juice and Its Component, Hesperidin, Decrease the Expression of Multidrug Resistance-Associated Protein 2 in Rat Small Intestine and Liver. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-8.	3.0	9
879	Flavonoids as Anticancer Agents: Recent Progress and State of the Art?. Current Organic Chemistry, 2011, 15, 2608-2615.	0.9	26

#	Article	IF	Citations
880	Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?. Current Pharmaceutical Design, 2011, 17, 3560-3576.	0.9	33
881	Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine, 2011, 13, e17.	1.6	266
882	Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 570-594.	0.9	185
883	Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma. Cancers, 2011, 3, 106-125.	1.7	39
884	Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. Journal of Drug Targeting, 2011, 19, 666-674.	2.1	3
885	Radical Decisions in Cancer: Redox Control of Cell Growth and Death. Cancers, 2012, 4, 442-474.	1.7	66
886	ATP hydrolysis-dependent conformational changes in the extracellular domain of ABCA1 are associated with apoA-I binding. Journal of Lipid Research, 2012, 53, 126-136.	2.0	42
887	Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations. Current Pharmaceutical Design, 2012, 18, 2811-2829.	0.9	47
888	Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 1264-1280.	0.9	167
889	Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene. American Journal of Veterinary Research, 2012, 73, 1477-1484.	0.3	8
890	Idiosyncratic reactions and metabolism of sulfur-containing drugs. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 467-485.	1.5	31
891	Folate Decorated Dual Drug Loaded Nanoparticle: Role of Curcumin in Enhancing Therapeutic Potential of Nutlin-3a by Reversing Multidrug Resistance. PLoS ONE, 2012, 7, e32920.	1.1	86
892	ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Frontiers in Oncology, 2012, 2, 178.	1.3	34
893	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.4	48
895	Drug Disposition in Pathophysiological Conditions. Current Drug Metabolism, 2012, 13, 1327-1344.	0.7	70
896	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2012, 64, 138-153.	6.6	903
897	Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. Xenobiotica, 2012, 42, 173-178.	0.5	31
898	Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. Journal of Gene Medicine, 2012, 14, 776-787.	1.4	26

#	Article	IF	Citations
899	Synthesis, characterization and anticancer activity of 3-aza-analogues of DP-7. Medicinal Chemistry Research, 2012, 21, 4002-4009.	1.1	13
901	Gene Expression Patterns and Life Cycle Responses of Toxicant-Exposed Chironomids. Environmental Science & Technology, 2012, 46, 12679-12686.	4.6	17
902	Purification and biochemical characterization of a novel proteinâ€"tongue cancer chemotherapy resistance-associated protein1 (TCRP1). Protein Expression and Purification, 2012, 82, 360-367.	0.6	20
903	Zearalenone exposure modulates the expression of ABC transporters and nuclear receptors in pregnant rats and fetal liver. Toxicology Letters, 2012, 211, 246-256.	0.4	49
904	ABCC1 polymorphisms in anthracyclineâ€induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biology International, 2012, 36, 79-86.	1.4	100
905	Genetic polymorphisms of drugâ€metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundamental and Clinical Pharmacology, 2012, 26, 295-306.	1.0	27
906	Barriers in the developing brain and Neurotoxicology. NeuroToxicology, 2012, 33, 586-604.	1.4	165
907	Membrane active antitumor activity of NK-18, a mammalian NK-lysin-derived cationic antimicrobial peptide. Biochimie, 2012, 94, 184-191.	1.3	43
908	YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. Cancer Letters, 2012, 314, 54-62.	3.2	12
909	Contribution of tumoral and host solute carriers to clinical drug response. Drug Resistance Updates, 2012, 15, 5-20.	6.5	25
910	Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer, 2012, 12, 381.	1.1	79
911	Potent Galloyl-Based Selective Modulators Targeting Multidrug Resistance Associated Protein 1 and P-glycoprotein. Journal of Medicinal Chemistry, 2012, 55, 424-436.	2.9	34
912	The effects of green tea polyphenols on drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 677-689.	1.5	51
913	Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Delivery, 2012, 19, 363-370.	2.5	50
914	Beyond the imaging: Limitations of cellular uptake study in the evaluation of nanoparticles. Journal of Controlled Release, 2012, 164, 170-176.	4.8	35
915	Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today, 2012, 7, 367-379.	6.2	292
916	Multifunctional Nanoparticles for Drug Delivery Applications. Nanostructure Science and Technology, 2012, , .	0.1	31
917	Dendrimer-Based Nanoparticle Therapies: Can Uniform Multifunctional Therapeutics Be Made with Current Chemical Approaches?. Nanostructure Science and Technology, 2012, , 295-313.	0.1	0

#	Article	IF	Citations
918	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Review of Clinical Pharmacology, 2012, 5, 69-89.	1.3	89
919	Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(Î²-L-Malic Acid). International Journal of Molecular Sciences, 2012, 13, 11681-11693.	1.8	71
920	Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 2012, 31, 58-72.	4.9	217
921	Small Molecule Drugs and Targeted Therapies for Neuroblastoma. , 0, , .		0
922	Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy. Oncology Letters, 2012, 4, 893-897.	0.8	7
923	Pharmacogenomics Dictate Pharmacokinetics: Polymorphisms in Drug-Metabolizing Enzymes and Drug-Transporters. , 0, , .		0
924	Age-Dependent and Tissue-Related Glutathione Redox Status in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 655-666.	1.2	81
925	Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer: A Case Presentation. Cancer and Clinical Oncology, 2012, 1, .	0.2	0
926	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	2.6	2,058
927	Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes and Cancer, 2012, 51, 832-840.	1.5	23
928	Nanostructure-based drug delivery systems for brain targeting. Drug Development and Industrial Pharmacy, 2012, 38, 387-411.	0.9	51
929	Study of the Anticancer Properties of Tin(IV) Carboxylate Complexes on a Panel of Human Tumor Cell Lines. ChemMedChem, 2012, 7, 301-310.	1.6	51
930	Cabazitaxel: de grote stap voorwaarts bij chemotherapie voor castratieresistent prostaatcarcinoom (CRPC)?. Tijdschrift Voor Urologie, 2012, 2, 45-49.	0.1	0
931	Involvement of multidrug resistance proteins (MRPs) in the efflux of vardenafil. Journal of Pharmaceutical Investigation, 2012, 42, 65-70.	2.7	1
932	Genome-wide analysis of the ATP-binding cassette (ABC) transporter gene family in the silkworm, Bombyx mori. Molecular Biology Reports, 2012, 39, 7281-7291.	1.0	62
933	Oxidative species and Sâ€glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. FEBS Journal, 2012, 279, 154-167.	2.2	39
934	The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells. European Journal of Pharmacology, 2012, 674, 112-125.	1.7	5
935	The effect of radixin knockdown on the expression and efflux function of MRP2 in SGC-7901 cells. European Journal of Pharmaceutical Sciences, 2012, 46, 426-434.	1.9	13

#	Article	IF	Citations
936	Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. Journal of Pharmacy and Pharmacology, 2012, 64, 1074-1083.	1.2	35
937	A Benzopyrane Derivative as a Pâ€Glycoprotein Stimulator: A Potential Agent to Decrease Î²â€Amyloid Accumulation in Alzheimerâ€™s Disease. ChemMedChem, 2012, 7, 391-395.	1.6	14
938	Overcoming tumor multidrug resistance using drugs able to evade Pâ€glycoprotein or to exploit its expression. Medicinal Research Reviews, 2012, 32, 1220-1262.	5.0	147
939	Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. BioMetals, 2012, 25, 149-163.	1.8	12
940	The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids and Barriers of the CNS, 2013, 10, 12.	2.4	98
941	Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. Inorganic Chemistry, 2013, 52, 12276-12291.	1.9	347
942	MicroRNAs as therapeutic targets in chemoresistance. Drug Resistance Updates, 2013, 16, 47-59.	6.5	133
943	Drug Resistance in Leishmania Parasites. , 2013, , .		13
944	A burst of ABC genes in the genome of the polyphagous spider mite Tetranychus urticae. BMC Genomics, 2013, 14, 317.	1.2	118
945	The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Molecular Cancer, 2013, 12, 47.	7.9	15
946	Enhanced intracellular drug delivery of pH-sensitive doxorubicin/poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 Td (glycol)-blo KB carcinoma cells. Biomaterials Science, 2013, 1, 361.	2.6	28
947	Nanoparticles as Bloodâ€“Brain Barrier Permeable CNS Targeted Drug Delivery Systems. Topics in Medicinal Chemistry, 2013, , 71-89.	0.4	22
948	Quantification and in situ localisation of abcb1 and abcc9genes in toxicant-exposed sea urchin embryos. Environmental Science and Pollution Research, 2013, 20, 8600-8611.	2.7	7
949	Breast Cancer Metastasis and Drug Resistance. , 2013, , .		12
950	Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology, 2013, 310, 115-123.	2.0	102
951	Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines. Molecular Biology Reports, 2013, 40, 6143-6150.	1.0	38
952	Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. International Journal for Parasitology: Drugs and Drug Resistance, 2013, 3, 143-153.	1.4	40
953	Nrf2 Prevents Initiation but Accelerates Progression through the Kras Signaling Pathway during Lung Carcinogenesis. Cancer Research, 2013, 73, 4158-4168.	0.4	208

#	Article	IF	Citations
954	Expression of the Nrf2â€system at the bloodâ€CSF barrier is modulated by neonatal inflammation and hypoxiaâ€ischemia. Journal of Inherited Metabolic Disease, 2013, 36, 479-490.	1.7	16
955	Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice. Cancer Chemotherapy and Pharmacology, 2013, 71, 503-509.	1.1	9
956	Effects of Food Lectins on the Transport System of Human Intestinal Caco-2 Cell Monolayers. Bioscience, Biotechnology and Biochemistry, 2013, 77, 1917-1924.	0.6	16
957	Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 237-252.	1.5	239
958	Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials, 2013, 34, 1-10.	5.7	111
959	Importance of Detecting Multidrug Resistance Proteins in Acute Leukemia Prognosis and Therapy. Journal of Clinical Laboratory Analysis, 2013, 27, 62-71.	0.9	25
960	Class III Î²-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal of Obstetrics and Gynecology, 2013, 209, 62.e1-62.e9.	0.7	26
961	Activityâ€“lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3728-3731.	1.0	11
962	Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. European Journal of Cancer, 2013, 49, 2331-2344.	1.3	60
963	N-Benzyloxycarbonyl-S-(2,4-dinitrophenyl)glutathione dibutyl diester is inhibitory to melarsoprol resistant cell lines overexpressing the T. bruceiMRPA transporter. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4351-4353.	1.0	5
964	Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity. Hearing Research, 2013, 299, 37-45.	0.9	84
965	Chemosensitizing acridones: In vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies. Journal of Molecular Graphics and Modelling, 2013, 40, 116-124.	1.3	13
966	Absorption: In Vitro Tests â€“ Cell Based. , 2013, , 745-777.		0
967	ABCB1-overexpressing MG63/DOX cell xenograft model: Maintain the MDR phenotypein vivo. Pharmaceutical Biology, 2013, 51, 968-973.	1.3	5
968	The Role of ABC Transporters in Drug-Resistant Leishmania. , 2013, , 237-258.		3
969	Dendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5â€²-triphosphate-binding cassette transporters far beyond an efflux pump. Clinical and Experimental Immunology, 2013, 172, 444-454.	1.1	11
970	Placental ABC transporters, cellular toxicity and stress in pregnancy. Chemico-Biological Interactions, 2013, 203, 456-466.	1.7	52
971	Breast Cancer Stem Cells and miRNAs. , 2013, , 367-383.		0

#	Article	IF	Citations
972	Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorganic and Medicinal Chemistry, 2013, 21, 1324-1332.	1.4	26
973	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1370-1374.	1.0	6
974	Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells. European Journal of Pharmacology, 2013, 721, 141-150.	1.7	7
975	Nanoencapsulation Enhances Epigallocatechin-3-gallate Stability and Its Antiatherogenic Bioactivities in Macrophages. Journal of Agricultural and Food Chemistry, 2013, 61, 9200-9209.	2.4	75
976	Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats. Acta Pharmacologica Sinica, 2013, 34, 473-479.	2.8	21
977	Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression. Pteridines, 2013, 24, 81-86.	0.5	3
978	Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma. BioMed Research International, 2013, 2013, 1-7.	0.9	43
979	Multidrug resistance-associated protein 2 (MRP2/ABCC2). , 2013, , 261-294.		1
980	Radioligands targeting Pâ€glycoprotein and other drug efflux proteins at the bloodâ€“brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 68-77.	0.5	45
981	ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20206-20211.	3.3	218
982	Inhibition of P-Glycoprotein Mediated Multidrug Resistance by Stemofoline Derivatives. Chemical and Pharmaceutical Bulletin, 2013, 61, 399-404.	0.6	19
983	DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. British Journal of Biomedical Science, 2013, 70, 31-40.	1.2	85
984	Multiple myeloma: the bone marrow microenvironment and its relation to treatment. British Journal of Biomedical Science, 2013, 70, 110-120.	1.2	47
985	Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology, 2013, 4, 28.	1.6	503
986	Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter. Lung Cancer: Targets and Therapy, 2013, 2013, 61.	1.3	4
987	Survival of Patients with Acute Lymphoblastic Leukemia. , 0, , .		0
988	Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer. PLoS ONE, 2013, 8, e63404.	1.1	111
989	Therapyâ€™s Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy. Frontiers in Pharmacology, 2013, 4, 58.	1.6	12

#	Article	IF	Citations
990	Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier. Current Drug Metabolism, 2013, 14, 625-640.	0.7	70
991	Drug resistance: as complex and diverse as the disease itself. , 0, , 921-928.		0
992	Renal Transporters and Biomarkers in Safety Assessment. , 0, , .		4
993	Implication of Clear Cell and Mucinous Histology. , 0, , .		0
994	Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy. Pakistan Journal of Medical Sciences, 2014, 30, 886-90.	0.3	6
995	Tryptophan as a Probe to Study the Anticancer Mechanism of Action and Specificity of Î±-Helical Anticancer Peptides. Molecules, 2014, 19, 12224-12241.	1.7	26
996	Is Glyburide Safe in Pregnancy?. Current Pharmaceutical Biotechnology, 2014, 15, 100-112.	0.9	13
997	Lapatinib Antagonizes Multidrug Resistance-Associated Protein 1-Mediated Multidrug Resistance by Inhibiting Its Transport Function. Molecular Medicine, 2014, 20, 390-399.	1.9	39
998	Mechanisms of Resistance to Anticancer Agents. , 2014, , 473-499.		0
1001	PEGylated polymer micelles for anticancer drug delivery carrier. , 2014, , 285-298.		2
1002	Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. Oncology Reports, 2014, 32, 1133-1139.	1.2	10
1003	Controlling the transmembrane transport of nucleosides. Supramolecular Chemistry, 2014, 26, 286-295.	1.5	9
1004	Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy. Tumor Biology, 2014, 35, 9897-9904.	0.8	34
1005	An improved and robust DNA immunization method to develop antibodies against extra-cellular loops of multi-transmembrane proteins. MAbs, 2014, 6, 95-107.	2.6	24
1007	A Drosophila ABC Transporter Regulates Lifespan. PLoS Genetics, 2014, 10, e1004844.	1.5	21
1008	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. International Journal of Molecular Sciences, 2014, 15, 6703-6716.	1.8	18
1009	Nanoscale drug delivery systems and the blood–brain barrier. International Journal of Nanomedicine, 2014, 9, 795.	3.3	155
1010	Gastrointestinal Mucosal Defense System. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2014, 6, 1-172.	0.3	1

#	Article	IF	Citations
1011	The putative multidrug resistance protein <scp>MRP</scp>â€7 inhibits methylmercuryâ€associated animal toxicity and dopaminergic neurodegeneration in Caenorhabditis elegans. Journal of Neurochemistry, 2014, 128, 962-974.	2.1	13
1012	Oral insulin delivery â€“ challenges and strategies. , 2014, , 113-168.		3
1013	KrÃ¼ppelâ€like factor 8 contributes to hypoxiaâ€induced <scp>MDR</scp> in gastric cancer cells. Cancer Science, 2014, 105, 1109-1115.	1.7	30
1014	A short update on cancer chemoresistance. Wiener Medizinische Wochenschrift, 2014, 164, 456-460.	0.5	29
1015	Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell International, 2014, 14, 68.	1.8	18
1016	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	1.9	30
1017	ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition. Cancer Drug Discovery and Development, 2014, , 373-400.	0.2	8
1018	Binding and inhibition of drug transport proteins by heparin. Cancer Biology and Therapy, 2014, 15, 135-145.	1.5	13
1019	Emodin Augments Cisplatin Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells via ROS-Dependent MRP1 Downregulation. BioMed Research International, 2014, 2014, 1-8.	0.9	44
1020	The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. European Journal of Pharmaceutical Sciences, 2014, 51, 96-109.	1.9	49
1021	Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnology Advances, 2014, 32, 789-803.	6.0	171
1022	Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Archives of Pharmacal Research, 2014, 37, 4-15.	2.7	144
1023	Computational models for predicting the interaction with ABC transporters. Drug Discovery Today: Technologies, 2014, 12, e69-e77.	4.0	14
1024	Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro. Tumor Biology, 2014, 35, 1157-1168.	0.8	11
1025	P-glycoprotein expression in Perna viridis after exposure to Prorocentrum lima, a dinoflagellate producing DSP toxins. Fish and Shellfish Immunology, 2014, 39, 254-262.	1.6	28
1026	The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1323-1330.	1.2	22
1027	Optimization in Drug Discovery. Methods in Pharmacology and Toxicology, 2014, , .	0.1	23
1028	The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice. Chemico-Biological Interactions, 2014, 224, 36-41.	1.7	15

#	Article	IF	Citations
1029	Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochemical Pharmacology, 2014, 92, 220-234.	2.0	76
1030	Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 599-616.	3.3	38
1031	Neuropharmacokinetics of two investigational compounds in rats: Divergent temporal profiles in the brain and cerebrospinal fluid. Biochemical Pharmacology, 2014, 91, 543-551.	2.0	11
1032	In Vitro Characterization of Intestinal and Hepatic Transporters: MRP2. Methods in Pharmacology and Toxicology, 2014, , 369-404.	0.1	0
1033	3-Methyladenine can depress drug efflux transporters via blocking the PI3Kâ€“AKTâ€“mTOR pathway thus sensitizing MDR cancer to chemotherapy. Journal of Drug Targeting, 2014, 22, 839-848.	2.1	17
1034	Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opinion on Drug Delivery, 2014, 11, 1601-1618.	2.4	33
1035	Development of Purine-Derived ¹⁸F-Labeled Pro-drug Tracers for Imaging of MRP1 Activity with PET. Journal of Medicinal Chemistry, 2014, 57, 1023-1032.	2.9	15
1036	3Î²-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. European Journal of Pharmacology, 2014, 741, 140-149.	1.7	36
1037	Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation. Antimicrobial Agents and Chemotherapy, 2014, 58, 1294-1301.	1.4	24
1038	Synthesis and Characterization of Macromolecular Rhodamine Tethers and Their Interactions with P-Glycoprotein. Bioconjugate Chemistry, 2014, 25, 1462-1469.	1.8	5
1039	Prediction of Pharmacokinetics and Drugâ€“Drug Interactions When Hepatic Transporters are Involved. Clinical Pharmacokinetics, 2014, 53, 659-678.	1.6	92
1040	Pharmacokinetic Pharmacogenomics. , 2014, , 341-364.		14
1041	Multidrug Resistance-Associated Protein (MRP1, 2, 4 and 5) Expression in Human Corneal Cell Culture Models and Animal Corneal Tissue. Molecular Pharmaceutics, 2014, 11, 2160-2171.	2.3	27
1042	Nanomaterial-Induced Autophagy: A New Reversal MDR Tool in Cancer Therapy?. Molecular Pharmaceutics, 2014, 11, 2527-2538.	2.3	55
1043	Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). Cancer Chemotherapy and Pharmacology, 2014, 73, 911-7.	1.1	4
1044	Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 581-597.	1.5	30
1045	RAD001 can reverse drug resistance of SGC7901/DDP cells. Tumor Biology, 2014, 35, 9171-9177.	0.8	13
1046	PET Radiotracers for Imaging Pâ€glycoprotein: The Challenge for Early Diagnosis in AD. ChemMedChem, 2014, 9, 38-42.	1.6	6

#	Article	IF	Citations
1047	Control of Metazoan Heme Homeostasis by a Conserved Multidrug Resistance Protein. Cell Metabolism, 2014, 19, 1008-1019.	7.2	61
1048	Potential modulation on BCRP and MRP 4 by onion: in vivo and ex-vivo studies. Journal of Functional Foods, 2014, 8, 243-251.	1.6	3
1049	Cloning and expression analysis of P-glycoprotein gene in Crassostrea ariakensis. Aquaculture, 2014, 418-419, 39-47.	1.7	13
1050	Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncology, 2014, 10, 655-669.	1.1	34
1051	In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells. Tumor Biology, 2014, 35, 8991-8998.	0.8	6
1052	Impact of ABC transporters, glutathione conjugates in MDR and their modulation by flavonoids: an overview. Medicinal Chemistry Research, 2014, 23, 1-15.	1.1	14
1053	Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 2014, 19, 13848-13877.	1.7	97
1054	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese Journal of Cancer, 2014, 33, 223-230.	4.9	48
1057	Genetic Toxicology. , 2014, , 1199-1230.		0
1060	MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Molecular Medicine Reports, 2015, 11, 625-632.	1.1	56
1061	The Expression and Function of ABC Transporters at the Blood-Brain Barrier. , 2015, , 172-214.		2
1062	Multiple ABC Transporters Efflux Baicalin. Phytotherapy Research, 2015, 29, 1987-1990.	2.8	47
1063	Identification and Functional Characterization of a GSH Conjugate Efflux Pathway in the Rat Lens. , 2015, 56, 5256.		5
1064	Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. Current Gene Therapy, 2015, 15, 151-160.	0.9	8
1065	Cancer Chemoprevention by Garlic - A Review. Hereditary Genetics: Current Research, 2015, 04, .	0.1	2
1066	Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections. Frontiers in Microbiology, 2015, 6, 948.	1.5	15
1067	Altered Gene Expression in the Schistosome-Transmitting Snail Biomphalaria glabrata following Exposure to Niclosamide, the Active Ingredient in the Widely Used Molluscicide Bayluscide. PLoS Neglected Tropical Diseases, 2015, 9, e0004131.	1.3	24
1068	Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21Î±-Methylmelianodiol in Lung Cancer Cells. PLoS ONE, 2015, 10, e0127841.	1.1	24

#	Article	IF	Citations
1069	Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. PLoS ONE, 2015, 10, e0131579.	1.1	36
1071	Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget, 2015, 6, 6776-6793.	0.8	102
1072	N -lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6601-6606.	3.3	63
1073	Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharmaceutica Sinica B, 2015, 5, 169-175.	5.7	166
1074	Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 27-52.	0.1	10
1075	The role of ABC transporters in ovarian cancer progression and chemoresistance. Critical Reviews in Oncology/Hematology, 2015, 96, 220-256.	2.0	139
1076	Minerals and Trace Elements. , 2015, , 673-807.		9
1077	Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines. Cancer Cell International, 2015, 15, 47.	1.8	41
1078	Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells. ACS Applied Materials & Interfaces, 2015, 7, 26315-26325.	4.0	48
1079	Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells. Molecular Medicine Reports, 2015, 11, 2315-2321.	1.1	27
1080	Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array. International Journal of Oncology, 2015, 46, 569-577.	1.4	1
1081	Transcriptional regulation, stabilization, and subcellular redistribution of multidrug resistance-associated protein 1 (MRP1) by glycogen synthase kinase 3Î±Î²: novel insights on modes of cadmium-induced cell death stimulated by MRP1. Archives of Toxicology, 2015, 89, 1271-1284.	1.9	18
1082	HtrA1 resensitizes multidrug-resistant hepatocellular carcinoma cells by targeting XIAP. Biomedicine and Pharmacotherapy, 2015, 70, 97-102.	2.5	17
1083	ABC Transporters and Neuroblastoma. Advances in Cancer Research, 2015, 125, 139-170.	1.9	25
1084	The Effect of Streptozotocin and Alloxan on the mRNA Expression of Rat Hepatic Transporters In Vivo. AAPS PharmSciTech, 2015, 16, 767-770.	1.5	5
1085	Understanding cancer and the anticancer activities of naphthoquinones â€“ a review. RSC Advances, 2015, 5, 20309-20338.	1.7	240
1086	The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 520-528.	1.8	45
1087	Mechanisms of Resistance to Photodynamic Therapy: An Update. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 29-63.	0.1	10

#	Article	IF	Citations
1088	Co-delivery of docetaxel and Poloxamer 235 by PLGAâ€“TPGS nanoparticles for breast cancer treatment. Materials Science and Engineering C, 2015, 49, 348-355.	3.8	68
1089	Targeted therapies in germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 363-369.	0.8	10
1090	Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Investigational New Drugs, 2015, 33, 290-299.	1.2	33
1091	Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors. BioMed Research International, 2015, 2015, 1-20.	0.9	207
1092	Stearidonic acid, a plant-based dietary fatty acid, enhances the chemosensitivity of canine lymphoid tumor cells. Biochemical and Biophysical Research Communications, 2015, 460, 1002-1007.	1.0	12
1093	The complexity of the Nrf2 pathway: beyond the antioxidant response. Journal of Nutritional Biochemistry, 2015, 26, 1401-1413.	1.9	325
1094	Molecular Therapies of Cancer. , 2015, , .		15
1095	An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. Journal of Materials Chemistry B, 2015, 3, 7153-7172.	2.9	108
1096	ABCB1 G2677T/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians. Epilepsy Research, 2015, 115, 100-108.	0.8	22
1097	Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1. Neurochemical Research, 2015, 40, 1546-1553.	1.6	14
1098	Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine, 2015, 10, 1165-1188.	1.7	48
1099	Strategies for drug delivery to the central nervous system by systemic route. Drug Delivery, 2015, 22, 243-257.	2.5	51
1100	Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 795-809.	1.5	60
1101	Radiopharmaceuticals for assessing ABC transporters at the bloodâ€“brain barrier. Clinical Pharmacology and Therapeutics, 2015, 97, 362-371.	2.3	25
1102	Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1821-1837.	1.5	2
1103	Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer and Metastasis Reviews, 2015, 34, 643-690.	2.7	191
1104	The Pharmacological and Physiological Role of Multidrug-Resistant Protein 4. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 358-375.	1.3	65
1105	Protein NMR. Biological Magnetic Resonance, 2015, , .	0.4	4

#	Article	IF	Citations
1106	ET-1 Induced Downregulation of MRP2 via miRNA 133a - A Marker for Tubular Nephrotoxicity?. American Journal of Nephrology, 2015, 41, 191-199.	1.4	10
1108	MRP1 and its role in anticancer drug resistance. Drug Metabolism Reviews, 2015, 47, 406-419.	1.5	110
1109	Bioinert Anodic Alumina Nanotubes for Targeting of Endoplasmic Reticulum Stress and Autophagic Signaling: A Combinatorial Nanotube-Based Drug Delivery System for Enhancing Cancer Therapy. ACS Applied Materials & Interfaces, 2015, 7, 27140-27151.	4.0	30
1110	The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. European Journal of Pharmacology, 2015, 746, 167-173.	1.7	48
1111	Proteomic profile in Perna viridis after exposed to Prorocentrum lima, a dinoflagellate producing DSP toxins. Environmental Pollution, 2015, 196, 350-357.	3.7	48
1112	Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. European Journal of Medicinal Chemistry, 2015, 89, 540-548.	2.6	31
1113	Preclinical Drug Development. , 0, , .		0
1114	Bioinformatics Analysis of the Human Surfaceome Reveals New Targets for a Variety of Tumor Types. International Journal of Genomics, 2016, 2016, 1-7.	0.8	13
1115	Microdialysis-directed Intra-tumor Pharmacokinetic Modeling of Methotrexate in Mice and Humans. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 239.	0.9	1
1116	Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. OncoTargets and Therapy, 2016, 9, 3501.	1.0	49
1117	Different Mechanisms of Drug Resistance in Myelodysplastic Syndromes and Acute Myeloid Leukemia. , 0, , .		1
1118	Asclepiasterol, a novel C21 steroidal glycoside derived fromAsclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression. Oncotarget, 2016, 7, 31466-31483.	0.8	26
1119	Biomolecular Network-Based Synergistic Drug Combination Discovery. BioMed Research International, 2016, 2016, 1-11.	0.9	22
1120	Alisol F 24 Acetate Enhances Chemosensitivity and Apoptosis of MCF-7/DOX Cells by Inhibiting P-Glycoprotein-Mediated Drug Efflux. Molecules, 2016, 21, 183.	1.7	14
1121	Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates. PLoS ONE, 2016, 11, e0160042.	1.1	22
1122	Drug-delivery nanocarriers to cross the bloodâ€“brain barrier. , 2016, , 333-370.		6
1123	Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy, 2016, 10, 1885.	2.0	291
1124	Multidrug ATPâ€binding cassette transporters are essential for hepatic development of Plasmodium sporozoites. Cellular Microbiology, 2016, 18, 369-383.	1.1	24

#	Article	IF	Citations
1125	Natural Polyphenols in Cancer Chemoresistance. Nutrition and Cancer, 2016, 68, 879-891.	0.9	48
1126	Molecular mechanisms for tumour resistance to chemotherapy. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 723-737.	0.9	304
1127	Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	4
1128	Targeting Chemotherapy Resistance in Glioblastoma Through Modulation of ABC Transporters. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 25-54.	0.1	1
1129	Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. Scientific Reports, 2016, 6, 31926.	1.6	30
1130	Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clinical Breast Cancer, 2016, 16, 335-343.	1.1	193
1131	Functional mesoporous silica nanoparticles (MSNs) for highly controllable drug release and synergistic therapy. Colloids and Surfaces B: Biointerfaces, 2016, 145, 217-225.	2.5	27
1132	Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. Biochemical and Biophysical Research Communications, 2016, 476, 35-41.	1.0	56
1133	Zinc Oxide Nanoparticles as Adjuvant To Facilitate Doxorubicin Intracellular Accumulation and Visualize pH-Responsive Release for Overcoming Drug Resistance. Molecular Pharmaceutics, 2016, 13, 1723-1730.	2.3	61
1134	Does the Clearance of Inhaled^{99m}Tc-Sestamibi Correlate with Multidrug Resistance Protein 1 Expression in the Human Lung?. Radiology, 2016, 280, 924-930.	3.6	10
1135	Role and modulation of drug transporters in HIV-1 therapy. Advanced Drug Delivery Reviews, 2016, 103, 121-143.	6.6	45
1136	A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. European Journal of Pharmaceutical Sciences, 2016, 93, 456-467.	1.9	22
1137	Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics. Advanced Science, 2016, 3, 1600134.	5.6	107
1138	Noninvasive Evaluation of Cellular Proliferative Activity in Brain Neurogenic Regions in Rats under Depression and Treatment by Enhanced [18F]FLT-PET Imaging. Journal of Neuroscience, 2016, 36, 8123-8131.	1.7	23
1139	Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacological Research, 2016, 111, 757-766.	3.1	19
1140	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates, 2016, 28, 65-81.	6.5	147
1141	The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1463-1477.	1.5	19
1142	The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Scientific Reports, 2016, 6, 26093.	1.6	116

#	Article	IF	Citations
1143	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	5.8	100
1145	Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Bloodâ€“Brain Barrier Model. Molecular Pharmaceutics, 2016, 13, 3341-3349.	2.3	36
1146	MiRNAs-mediated cisplatin resistance in breast cancer. Tumor Biology, 2016, 37, 12905-12913.	0.8	27
1147	Antibacterial and Anticancer Properties ofDolichos kilimandscharicus(Fabaceae). Journal of Biologically Active Products From Nature, 2016, 6, 112-135.	0.1	1
1148	PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Scientific Reports, 2016, 6, 30788.	1.6	43
1149	A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy. Scientific Reports, 2016, 6, 32363.	1.6	23
1150	pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Central Science, 2016, 2, 802-811.	5.3	101
1151	Synthesis and Antineoplastic Evaluation of Novel Unsymmetrical 1,3,4-Oxadiazoles. Journal of Medicinal Chemistry, 2016, 59, 10451-10469.	2.9	31
1152	Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Systems Biology, 2016, 10, 33.	3.0	13
1153	Metabolism and Drugâ€“Drug Interaction in Pregnant Mother/Placenta/Fetus. Methods in Pharmacology and Toxicology, 2016, , 1-16.	0.1	1
1154	Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line. DARU, Journal of Pharmaceutical Sciences, 2016, 24, 17.	0.9	36
1155	The role of glucuronidation in drug resistance. , 2016, 159, 35-55.		75
1156	Human ABC Transporter ABCC11: Looking Back Pioneersâ€™ Odyssey and Creating a New Path Toward Clinical Application. , 2016, , 297-318.		1
1157	ABC Transporters - 40 Years on. , 2016, , .		17
1158	Bioinformatic survey of ABC transporters in dermatophytes. Gene, 2016, 576, 466-475.	1.0	8
1159	Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates, 2016, 24, 34-54.	6.5	124
1160	Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 2016, 77, 1103-1124.	1.1	646
1161	Dietary Isoflavones as Modulators of Drug Metabolizing Enzymes and Transporters: Effect on Prescription Medicines. Critical Reviews in Food Science and Nutrition, 2016, 56, S95-S109.	5.4	10

#	Article	IF	Citations
1162	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Letters, 2016, 370, 153-164.	3.2	595
1163	InÂvivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier. Biomaterials, 2016, 75, 71-81.	5.7	66
1164	Nitrobenzoxadiazole-based GSTP1-1 inhibitors containing the full peptidyl moiety of (pseudo)glutathione. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 924-930.	2.5	10
1165	Molecular mechanisms of drug resistance and its reversal in cancer. Critical Reviews in Biotechnology, 2016, 36, 716-726.	5.1	260
1166	A Multiâ€Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance. ChemMedChem, 2017, 12, 250-256.	1.6	21
1167	Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. Journal of Controlled Release, 2017, 253, 82-96.	4.8	67
1168	Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis , through regulating different signaling pathways. Chinese Journal of Natural Medicines, 2017, 15, 15-40.	0.7	71
1169	Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain. Neuropharmacology, 2017, 117, 182-194.	2.0	65
1171	Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. International Nano Letters, 2017, 7, 91-122.	2.3	122
1172	Placental transporter localization and expression in the Human: the importance of species, sex, and gestational age differencesâ€. Biology of Reproduction, 2017, 96, 733-742.	1.2	93
1173	Joint-based description of protein structure: its application to the geometric characterization of membrane proteins. Scientific Reports, 2017, 7, 1056.	1.6	3
1174	Computational prediction of drug-drug interactions based on drugs functional similarities. Journal of Biomedical Informatics, 2017, 70, 54-64.	2.5	127
1175	The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 741-753.	1.5	8
1176	Molecular properties associated with transporter-mediated drug disposition. Advanced Drug Delivery Reviews, 2017, 116, 92-99.	6.6	22
1177	The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opinion on Therapeutic Targets, 2017, 21, 511-530.	1.5	101
1178	Salinomycin: A new paradigm in cancer therapy. Tumor Biology, 2017, 39, 101042831769503.	0.8	102
1179	Geniposide reverses multidrug resistance in vitro and in vivo by inhibiting the efflux function and expression of P-glycoprotein. Experimental and Therapeutic Medicine, 2017, 13, 437-442.	0.8	12
1181	Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5. Canadian Journal of Physiology and Pharmacology, 2017, 95, 580-585.	0.7	3

#	Article	IF	Citations
1182	Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. Oncology Letters, 2017, 14, 4270-4276.	0.8	15
1183	Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 689-694.	0.7	7
1184	Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis, 2017, 6, e373-e373.	2.1	186
1185	Modeling the Transfer of Drug Resistance in Solid Tumors. Bulletin of Mathematical Biology, 2017, 79, 2394-2412.	0.9	9
1186	Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. European Journal of Pharmaceutical Sciences, 2017, 109, 631-637.	1.9	17
1187	Magnetic-Immuno-Loop-Mediated Isothermal Amplification Based on DNA Encapsulating Liposome for the Ultrasensitive Detection of P-glycoprotein. Scientific Reports, 2017, 7, 9312.	1.6	7
1188	Natural products to prevent drug resistance in cancer chemotherapy: a review. Annals of the New York Academy of Sciences, 2017, 1401, 19-27.	1.8	148
1189	Vitamin B12 and Folic Acid in Nutritional Anemia in Children. , 2017, , 149-174.		0
1190	Evaluation of the Antiproliferative Activity ofMaerua edulis(Capparaceae)on Jurkat-T cells. Journal of Biologically Active Products From Nature, 2017, 7, 214-227.	0.1	1
1192	Bloodâ€“Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. AAPS Journal, 2017, 19, 1600-1614.	2.2	23
1193	Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Delivery, 2017, 24, 1909-1926.	2.5	149
1194	Plasma PPi Deficiency Is the Major, but NotÂthe Exclusive, Cause of Ectopic Mineralization in an Abcc6 Mouse Model of PXE. Journal of Investigative Dermatology, 2017, 137, 2336-2343.	0.3	44
1195	Genome-wide analysis of ATP-binding cassette (ABC) transporters in the sweetpotato whitefly, Bemisia tabaci. BMC Genomics, 2017, 18, 330.	1.2	60
1196	The choroid plexus in health and in disease: dialogues into and out of the brain. Neurobiology of Disease, 2017, 107, 32-40.	2.1	77
1197	Structureâ^'activity relationship study of novel 2-aminobenzofuran derivatives as P-glycoprotein inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 1023-1035.	2.6	18
1198	Regulation of Drug Transporters byÂInflammation. , 2017, , 59-89.		2
1199	Early use of chemotherapy in metastatic prostate cancer. Cancer Treatment Reviews, 2017, 55, 218-224.	3.4	19
1200	Association between Twist and multidrug resistance geneâ€'associated proteins in TaxolÃ¯Â¿Â½â€'resistant MCFâ€'7 cells and a 293 cell model of Twist overexpression. Oncology Letters, 2018, 15, 1058-1066.	0.8	6

#	Article	IF	Citations
1201	Cellular efflux transporters and the potential role of natural products in combating efflux mediated drug resistance. Frontiers in Bioscience - Landmark, 2017, 22, 732-756.	3.0	42
1202	Pathogenesis of Idiosyncratic Drug Induced Liver Injury. , 2017, , 87-100.		3
1203	Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity. Pharmaceutics, 2017, 9, 8.	2.0	9
1204	CLIC1 Induces Drug Resistance in Human Choriocarcinoma Through Positive Regulation of MRP1. Oncology Research, 2017, 25, 863-871.	0.6	22
1205	The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes, 2017, 8, 158.	1.0	36
1206	Evolutionary Trajectories of Entomopathogenic Fungi ABC Transporters. Advances in Genetics, 2017, 98, 117-154.	0.8	20
1207	Brain and the Drug Transporters. , 2017, , 35-67.		1
1208	Nanoparticle System for Anticancer Drug Delivery: Targeting to Overcome Multidrug Resistance. , 2017, , 159-169.		7
1209	The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Advanced Pharmaceutical Bulletin, 2017, 7, 339-348.	0.6	1,143
1210	CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 157.	3.5	52
1211	Changes in the serum, liver, and renal cortical lipids and electrolytesin rabbits with cisplatin-induced nephrotoxicity. Turkish Journal of Medical Sciences, 2017, 47, 1019-1027.	0.4	2
1212	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget, 2017, 8, 9388-9398.	0.8	33
1213	Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901. World Journal of Gastroenterology, 2017, 23, 1189.	1.4	12
1214	Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget, 2017, 8, 101965-101983.	0.8	20
1215	Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies. Computational Biology and Chemistry, 2018, 74, 63-75.	1.1	14
1216	The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in Î²-tubulin. Journal of Biological Chemistry, 2018, 293, 9461-9472.	1.6	40
1217	Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. Biomaterials, 2018, 171, 207-218.	5.7	289
1218	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2420-2427.	1.4	14

#	Article	IF	Citations
1219	Quercetin reversed MDR in breast cancer cells through downâ€regulating Pâ€gp expression and eliminating cancer stem cells mediated by YBâ€1 nuclear translocation. Phytotherapy Research, 2018, 32, 1530-1536.	2.8	89
1220	Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer. Bioscience Reports, 2018, 38, .	1.1	16
1221	Crossâ€Linking of Thiolated Paclitaxelâ€“Oligo(pâ€phenylene vinylene) Conjugates Aggregates inside Tumor Cells Leads to â€œChemical Locksâ€•That Increase Drug Efficacy. Advanced Materials, 2018, 30, 1704888.	11.1	61
1222	P-glycoprotein polymorphism and levothyroxine bioavailability in hypothyroid patients. Saudi Pharmaceutical Journal, 2018, 26, 274-278.	1.2	3
1223	Pathways Linked to Cancer Chemoresistance and Their Targeting by Nutraceuticals. , 2018, , 1-30.		5
1224	Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 470-479.	1.9	20
1225	Adaptation to the deep-sea hydrothermal vents and cold seeps: Insights from the transcriptomes of Alvinocaris longirostris in both environments. Deep-Sea Research Part I: Oceanographic Research Papers, 2018, 135, 23-33.	0.6	20
1226	New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. Journal of Medicinal Chemistry, 2018, 61, 3389-3408.	2.9	35
1227	Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors. Oncology Letters, 2018, 15, 4376-4382.	0.8	11
1228	Antimicrobial effects of N-benzyloxycarbonyl-S-(2,4-dinitrophenyl) glutathione diesters against chloroquinine sensitive (NF54) and resistant (K1) strains of Plasmodium falciparum. Bioorganic Chemistry, 2018, 78, 115-118.	2.0	1
1229	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Advances in Biological Regulation, 2018, 68, 77-87.	1.4	132
1230	RNA interference-based therapy and its delivery systems. Cancer and Metastasis Reviews, 2018, 37, 107-124.	2.7	201
1231	St. Johnâ€™s Wort accelerates the liver clearance of technetium-99-sestamibi in rats. Nuclear Medicine Communications, 2018, 39, 839-844.	0.5	4
1232	Molecular Biology of ABC Transporters. , 2018, , 180-220.		0
1233	Drug Transporters. , 2018, , 331-348.		0
1234	ADME Processes in Pharmaceutical Sciences. , 2018, , .		16
1235	Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release, 2018, 291, 37-64.	4.8	134
1236	In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats. Pharmaceutics, 2018, 10, 125.	2.0	5

#	Article	IF	Citations
1237	Regulation of Hepatobiliary Transporters During Liver Injury. , 2018, , 215-276.		0
1238	Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening. PLoS ONE, 2018, 13, e0205175.	1.1	16
1239	Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. Cancer Cell International, 2018, 18, 128.	1.8	50
1240	The Role of ABC Transporters in Drug-Resistant Leishmania. , 2018, , 247-272.		1
1241	Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 505-512.	1.5	17
1242	Photoresponsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp shRNA and Doxorubicin To Optimize and Enhance Synergistic Therapy of Multidrug-Resistant Cancer. ACS Applied Materials & Interfaces, 2018, 10, 19416-19427.	4.0	67
1243	Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition. Future Medicinal Chemistry, 2018, 10, 1349-1360.	1.1	18
1245	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research, 2018, 24, 5239-5249.	3.2	21
1246	Metabolic Reprogramming During Multidrug Resistance in Leukemias. Frontiers in Oncology, 2018, 8, 90.	1.3	19
1247	An Outward-Facing Aromatic Amino Acid Is Crucial for Signaling between the Membrane-Spanning and Nucleotide-Binding Domains of Multidrug Resistance Protein 1 (MRP1; ABCC1). Molecular Pharmacology, 2018, 94, 1069-1078.	1.0	16
1248	ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. International Journal of Oncology, 2018, 53, 1055-1068.	1.4	36
1249	The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases. Biomedicine and Pharmacotherapy, 2018, 105, 870-878.	2.5	18
1250	Drug Resistance in Leishmania Parasites. , 2018, , .		3
1251	T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways. MAbs, 2018, 10, 1-15.	2.6	15
1252	Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer. , 2018, , 121-134.		0
1253	Role of Piperine in Chemoresistance. , 2018, , 259-286.		14
1254	Multiâ€'kinase inhibitors and cisplatin for head and neck cancer treatment in vitro. Oncology Letters, 2019, 18, 2220-2231.	0.8	8
1255	Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?. Nanomedicine, 2019, 14, 2083-2100.	1.7	29

#	Article	IF	Citations
1256	Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells. Critical Reviews in Microbiology, 2019, 45, 334-353.	2.7	41
1257	Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients . Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 87-95.	0.4	17
1258	Cell proliferation and invasion are regulated differently by EGFR and MRP1 in T-DM1-resistant breast cancer cells. Scientific Reports, 2019, 9, 16383.	1.6	6
1259	A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer. Biomaterials Science, 2019, 7, 4748-4757.	2.6	15
1260	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 8578-8608.	2.9	29
1261	The potentially protective role of ATP-binding cassette transporters in preeclampsia via Nrf2. Pregnancy Hypertension, 2019, 18, 21-28.	0.6	13
1262	Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review. Expert Review of Neurotherapeutics, 2019, 19, 545-555.	1.4	9
1263	The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1390-1397.	1.1	26
1264	CircABCC2 Regulates Hepatocellular Cancer Progression by Decoying MiR-665. Journal of Cancer, 2019, 10, 3893-3898.	1.2	23
1265	Effects of histone deacetylase inhibitors on ATPâ€'binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells. Oncology Letters, 2019, 18, 63-71.	0.8	9
1266	BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/Î²-catenin signaling. In Vitro Cellular and Developmental Biology - Animal, 2019, 55, 445-452.	0.7	10
1267	Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 2340.	1.8	165
1268	Chemoresistance mechanisms of breast cancer and their countermeasures. Biomedicine and Pharmacotherapy, 2019, 114, 108800.	2.5	214
1269	MicroRNAs as markers to monitor endothelinâ€1 signalling and potential treatment in renal disease: Carcinoma â˜' proteinuric damage â˜' toxicity. Biology of the Cell, 2019, 111, 169-186.	0.7	6
1270	Pharmacological characterization of the 3D MucilAirâ„¢ nasal model. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 186-196.	2.0	39
1271	Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance. Nano Letters, 2019, 19, 2968-2978.	4.5	81
1272	Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Molecular Cancer, 2019, 18, 69.	7.9	78
1273	Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells. Scientific Reports, 2019, 9, 1864.	1.6	8

#	Article	IF	Citations
1274	The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Scientific Reports, 2019, 9, 17639.	1.6	87
1275	A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity. Asian Journal of Pharmaceutical Sciences, 2019, 14, 658-667.	4.3	18
1276	Glutathione: subcellular distribution and membrane transport. Biochemistry and Cell Biology, 2019, 97, 270-289.	0.9	75
1277	Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. Acta OncolÃ³gica, 2019, 58, 168-174.	0.8	4
1278	Non-targeted metabolomic analysis on multidrug resistance hepatocellular carcinoma cell and reversal effect of annonaceous acetogenins. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 489-495.	1.4	6
1279	Identification of Smac mimetics as novel substrates for p-glycoprotein. Cancer Letters, 2019, 440-441, 126-134.	3.2	8
1280	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology, 2019, 3, 235-254.	2.3	47
1281	Porous Silicon Nanoparticles for Applications in Nano-medicine. , 2019, , 211-226.		1
1282	Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. Journal of Oncology Pharmacy Practice, 2020, 26, 434-444.	0.5	93
1283	Genetic contribution of ABCC2 to Dubinâ€Johnson syndrome and inherited cholestatic disorders. Liver International, 2020, 40, 163-174.	1.9	27
1284	1H NMR-Based Metabolic Profiles Delineate the Anticancer Effect of Vitamin C and Oxaliplatin on Hepatocellular Carcinoma Cells. Journal of Proteome Research, 2020, 19, 781-793.	1.8	11
1285	Self-assembling mertansine prodrug improves tolerability and efficacy of chemotherapy against metastatic triple-negative breast cancer. Journal of Controlled Release, 2020, 318, 234-245.	4.8	10
1286	Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-30.	1.9	13
1287	Tumor-targeted Strategies. , 2020, , 27-55.		0
1288	Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review. European Journal of Medicinal Chemistry, 2020, 204, 112609.	2.6	155
1289	Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia, 2021, 35, 2092-2096.	3.3	2
1290	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 8505.	1.8	12
1291	Disruption of small molecule transporter systems by Transporterâ€Interfering Chemicals (TICs). FEBS Letters, 2020, 594, 4158-4185.	1.3	12

#	Article	IF	Citations
1292	Mahonia aquifolium Extracts Promote Doxorubicin Effects against Lung Adenocarcinoma Cells In Vitro. Molecules, 2020, 25, 5233.	1.7	4
1293	Identification new potential multidrug resistance proteins of Saccharomyces cerevisiae. Journal of Microbiological Methods, 2020, 176, 106029.	0.7	4
1294	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 177-215.	0.9	6
1295	ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biology and Medicine, 2020, 17, 253-269.	1.4	81
1296	Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR. FEBS Letters, 2020, 594, 4001-4011.	1.3	22
1297	Enhancing Chemotherapy by RNA Interference. BIO Integration, 2020, 1, .	0.9	11
1298	Advance on the absorption, metabolism, and efficacy exertion of quercetin and its important derivatives. Food Frontiers, 2020, 1, 420-434.	3.7	52
1299	The functional role of long noncoding RNA in resistance to anticancer treatment. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092785.	1.4	30
1300	Reliable measurement of free Ca2+ concentrations in the ER lumen using Mag-Fluo-4. Cell Calcium, 2020, 87, 102188.	1.1	29
1301	Prevalence of ABCC3â€1767G/A polymorphism among patients with antiretroviralâ€associated hepatotoxicity. Molecular Genetics & Genomic Medicine, 2020, 8, e1124.	0.6	3
1302	Phytochemicals: Potential Lead Molecules for MDR Reversal. Frontiers in Pharmacology, 2020, 11, 832.	1.6	50
1303	Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-Î² and paclitaxel in A549 cells. Biomedicine and Pharmacotherapy, 2020, 129, 110434.	2.5	5
1304	Chronic exposure of human glioblastoma tumors to low concentrations of a pesticide mixture induced multidrug resistance against chemotherapy agents. Ecotoxicology and Environmental Safety, 2020, 202, 110940.	2.9	14
1305	Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucose-dependent alterations in reactive oxygen species, P-glycoprotein and DKK4. Journal of Biosciences, 2020, 45, 1.	0.5	15
1306	The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis. Expert Opinion on Drug Delivery, 2020, 17, 523-541.	2.4	52
1307	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. International Journal of Molecular Sciences, 2020, 21, 401.	1.8	48
1308	Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal. Microorganisms, 2020, 8, 154.	1.6	103
1309	Synthesis and anticancer property of three new Ca (II) compounds derived from tetrazole carboxylate ligands. Inorganica Chimica Acta, 2020, 509, 119659.	1.2	11

#	Article	IF	Citations
1310	Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. , 2020, 213, 107554.		83
1311	The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Frontiers in Pharmacology, 2020, 11, 343.	1.6	258
1312	One ring to bring them all and in the darkness bind them: The trafficking of heme without deliverers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118881.	1.9	46
1313	Selenium-doped calcium phosphate biomineral reverses multidrug resistance to enhance bone tumor chemotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102322.	1.7	6
1314	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
1315	ABC Transporters: Multidrug Resistance-Associated Proteins. , 2021, , 1-8.		0
1316	Drug resistance in gynecologic cancers: Findings and underlying mechanisms. , 2021, , 49-75.		1
1317	Drug Transporters: Efflux. , 2021, , .		0
1318	Overview of mechanisms of chemoresistance in ovarian cancer. , 2021, , 25-42.		1
1320	ABC Transporters: An Overview. , 2021, , 1-10.		4
1321	Bioenergetics in environmental adaptation and stress tolerance of aquatic ectotherms: linking physiology and ecology in a multi-stressor landscape. Journal of Experimental Biology, 2021, 224, .	0.8	88
1322	Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells. Scientific Reports, 2021, 11, 4392.	1.6	3
1323	Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells. Anticancer Research, 2021, 41, 1429-1438.	0.5	1
1324	The changes of MRP2 expression in three kinds of pulmonary inflammation models: the downregulation occurred in cigarette smoke extract (CSE) stimulation group and CSE plus LPS stimulation group, unchanged in LPS stimulation group. Toxicology Mechanisms and Methods, 2021, 31, 413-424.	1.3	2
1325	Clinical Significance and Oncogenic Activity of GRWD1 Overexpression in the Development of Colon Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 1565-1580.	1.0	7
1326	Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes. Pharmacogenomics Journal, 2021, 21, 510-519.	0.9	6
1327	A Systematic Strategy of Combinational Blow for Overcoming Cascade Drug Resistance via NIRâ€Lightâ€Triggered Hyperthermia. Advanced Materials, 2021, 33, e2100599.	11.1	78
1328	Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells. Nanomaterials, 2021, 11, 1365.	1.9	4

#	Article	IF	Citations
1329	Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/Î²-catenin signaling. Translational Cancer Research, 2021, 10, 2437-2450.	0.4	7
1330	HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4. Frontiers in Oncology, 2021, 11, 645979.	1.3	3
1331	A quantitative structureâ€“activity relationship study on CXL017 derivatives as effective drugs for cancer treatment. Journal of the Chinese Chemical Society, 0, , .	0.8	1
1332	The Role of Tumour Metabolism in Cisplatin Resistance. Frontiers in Molecular Biosciences, 2021, 8, 691795.	1.6	36
1334	Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 651269.	1.1	10
1335	The role of CD44 in cancer chemoresistance: A concise review. European Journal of Pharmacology, 2021, 903, 174147.	1.7	49
1336	Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives. Environmental Science and Pollution Research, 2021, 28, 49447-49466.	2.7	29
1337	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	0.7	57
1338	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Molecular Cancer Therapeutics, 2021, 20, 2539-2552.	1.9	2
1339	C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Caseâ€“Control and Meta-Analysis Study. Genes, 2021, 12, 1419.	1.0	5
1340	Effect of prednisolone pre-treatment on cat lymphoma cell sensitivity towards chemotherapeutic drugs. Research in Veterinary Science, 2021, 138, 178-187.	0.9	3
1341	Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Humanâ€™s Platelet Activation. Protein and Peptide Letters, 2021, 28, 983-995.	0.4	2
1342	Drug resistance: from bacteria to cancer. Molecular Biomedicine, 2021, 2, 27.	1.7	14
1343	Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer. European Journal of Pharmaceutical Sciences, 2021, 164, 105890.	1.9	38
1344	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	1.3	6
1345	What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. Coordination Chemistry Reviews, 2021, 449, 214210.	9.5	65
1347	Selfâ€Activated Cascadeâ€Responsive Sorafenib and USP22 shRNA Coâ€Delivery System for Synergetic Hepatocellular Carcinoma Therapy. Advanced Science, 2021, 8, 2003042.	5.6	30
1349	Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via ZEB1-AS1/miR-186-5p/ABCC1 Axis. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 673-683.	0.7	7

#	Article	IF	Citations
1350	Renal handling of drugs and xenobiotics. , 2003, , 21-46.		7
1351	Pathobiology of Antineoplastic Therapy in Undifferentiated Thyroid Cancer. , 2004, 122, 357-367.		2
1352	Absorption â€“Âin vitro TestsÂâ€“ Cell Based. , 2006, , 437-459.		2
1353	Adverse reactions and their mechanisms from nimesulide. , 2005, , 315-415.		10
1354	Drug Transporters At Brain Barriers. Advances in Experimental Medicine and Biology, 2013, , 20-69.	0.8	17
1355	Role of Multidrug Resistance Proteins (MRP) in Resistance to Antifolates and Folate Homeostasis. , 2002, , 643-647.		2
1356	Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. Methods in Molecular Biology, 2014, 1175, 91-120.	0.4	20
1357	ABC Transporter Proteins and Cellular Drug Resistance. , 2004, , 129-162.		2
1358	Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors. , 2006, , 241-260.		2
1359	Cisplatin Resistance. , 2006, , 283-307.		7
1360	Regulation of the Cellular Pharmacology and Cytotoxicity of Cisplatin by Copper Transporters. , 2006, , 309-327.		2
1362	Pharmacogenetics of Membrane Transporters. Methods in Molecular Biology, 2008, 448, 41-62.	0.4	21
1363	Drug Resistance Transporters in AML. , 2007, , 163-173.		1
1364	Cellular Resistance to Oxaliplatin and Drug Accumulation Defects. , 2009, , 115-124.		4
1365	Drug Permeation Across the Fetal Maternal Barrier. , 2009, , 153-170.		1
1366	Human Melanoma: Drug Resistance. Recent Results in Cancer Research, 2003, 161, 93-110.	1.8	20
1367	ABC Transporter-Mediated Multidrug-Resistant Cancer. Advances in Experimental Medicine and Biology, 2019, 1141, 549-580.	0.8	150
1368	Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neurotherapeutics, 2005, 2, 86-98.	2.1	4

#	Article	IF	Citations
1369	Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. Pharmaceutical Research, 2005, 22, 1837.	1.7	6
1370	Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artificial Intelligence in Medicine, 2017, 83, 35-43.	3.8	71
1371	The human ATP-binding cassette (ABC) transporter superfamily. Journal of Lipid Research, 2001, 42, 1007-1017.	2.0	965
1373	In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. , 0, .		5
1374	Mammalian multidrug-resistance proteins (MRPs). Essays in Biochemistry, 2011, 50, 179-207.	2.1	184
1375	The Human ATP-Binding Cassette (ABC) Transporter Superfamily. Genome Research, 2001, 11, 1156-1166.	2.4	932
1376	Multidrug resistance related molecules in human and murine lung. Journal of Clinical Pathology, 2002, 55, 332-339.	1.0	142
1377	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation, 2011, 121, 2888-2897.	3.9	83
1378	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 2119-2130.	3.9	56
1380	Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Medical Science Monitor, 2012, 18, BR383-BR388.	0.5	21
1381	Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study. PLoS ONE, 2011, 6, e26091.	1.1	72
1382	Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance. PLoS ONE, 2012, 7, e30804.	1.1	44
1383	The Absence of Mrp4 Has No Effect on the Recruitment of Neutrophils and Eosinophils into the Lung after LPS, Cigarette Smoke or Allergen Challenge. PLoS ONE, 2013, 8, e61193.	1.1	3
1384	HZ08 Reverse P-Glycoprotein Mediated Multidrug Resistance In Vitro and In Vivo. PLoS ONE, 2015, 10, e0116886.	1.1	10
1385	BCRP/ABCG2 inhibitors: a patent review (2009-present). Expert Opinion on Therapeutic Patents, 2015, 25, 1229-37.	2.4	15
1386	Interaction between Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1 and GTP-H-Ras: Implications for Aggressiveness of Human Mammary Epithelial Cells and Drug Resistance. Journal of Cancer Prevention, 2020, 25, 234-243.	0.8	6
1388	The MRP4/ABCC4 Gene Encodes a Novel Apical Organic Anion Transporter in Human Kidney Proximal Tubules. Journal of the American Society of Nephrology: JASN, 2002, 13, 595-603.	3.0	433
1389	Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.. Acta Biochimica Polonica, 2019, 52, 609-627.	0.3	104

#	Article	IF	Citations
1390	ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget, 2016, 7, 55449-55457.	0.8	20
1391	ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines. Oncotarget, 2016, 7, 70011-70027.	0.8	28
1392	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget, 2017, 8, 93785-93799.	0.8	22
1393	LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget, 2017, 8, 91990-92003.	0.8	73
1394	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget, 2018, 9, 16185-16196.	0.8	26
1395	The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget, 2015, 6, 10195-10206.	0.8	56
1396	A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. Oncotarget, 2015, 6, 31104-31118.	0.8	18
1397	A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget, 2012, 3, 640-650.	0.8	79
1398	MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design. Current Medicinal Chemistry, 2019, 26, 1270-1307.	1.2	18
1399	ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine. Current Medicinal Chemistry, 2019, 26, 1155-1184.	1.2	11
1400	Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?. Current Pharmaceutical Design, 2014, 20, 1422-1449.	0.9	201
1401	Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance. Current Drug Metabolism, 2020, 21, 199-210.	0.7	10
1402	CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function. Current Genomics, 2003, 4, 225-235.	0.7	14
1403	Pharmacogenetics of Adverse Drug Reactions. , 2006, , 65-89.		1
1404	Identification and characterisation of a multidrug resistance-related protein mRNA in the blue mussel Mytilus edulis. Marine Ecology - Progress Series, 2005, 286, 167-175.	0.9	20
1405	Identification and ranking of important bio-elements in drug-drug interaction by Market Basket Analysis. BioImpacts, 2020, 10, 97-104.	0.7	8
1406	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. World Journal of Gastroenterology, 2018, 24, 3222-3238.	1.4	77
1407	Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel7402. World Journal of Gastroenterology, 2002, 8, 1029.	1.4	37

#	Article	IF	Citations
1408	Hydroxychloroquine reverses the drug resistance of leukemic K562/ADMï¿½cells by inhibiting autophagy. Molecular Medicine Reports, 2019, 20, 3883-3892.	1.1	5
1409	Targeting Multidrug Resistance with Small Molecules for Cancer Therapy. Biomolecules and Therapeutics, 2010, 18, 375-385.	1.1	6
1410	Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncology Reviews, 2020, 14, 448.	0.8	38
1411	Ovarian cancer: An ever challenging malady. Biomedical Research Journal, 2014, 1, 34.	0.4	3
1412	Marine-derived fungi extracts enhance the cytotoxic activity of doxorubicin in nonsmall cell lung cancer cells A459. Pharmacognosy Research (discontinued), 2017, 9, 92.	0.3	16
1413	Drug Metabolism and Pharmacokinetics of Organosulfur Compounds from Garlic. Journal of Drug Metabolism & Toxicology, 2013, 04, .	0.1	16
1414	Natural Products Modulate the Multifactorial Multidrug Resistance of Cancer. Pharmacology & Pharmacy, 2015, 06, 146-176.	0.2	33
1415	New Insights into Toxicity and Drug Testing. , 2013, , .		6
1416	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
1417	Multidrug Resistance-Associated Protein 1 Predicts Relapse in Iranian Childhood Acute Lymphoblastic Leukemia. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2285-2289.	0.5	10
1418	Effect of Variation of ABCB1 and ABCC3 Genotypes on the Survival of Bone Tumor Cases after Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4595-4598.	0.5	27
1419	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. Journal of Biomedical Research, 2016, 30, 120-133.	0.7	13
1420	Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2). Journal of Medicinal Chemistry, 2021, 64, 14311-14331.	2.9	11
1421	A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 2021, 40, 6395-6405.	2.6	41
1422	TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer. Journal of Ovarian Research, 2021, 14, 128.	1.3	15
1424	Squamous cell and adeno cancer antigens recognized by cytotoxic T lymphocytes. , 2003, , 75-96.		0
1426	Transcriptional Regulation of Hepatobiliary Transporters. , 2004, , 96-111.		0
1427	Bodipy-FL-Verapamil: A Fluorescent Probe for the Study of Multidrug Resistance Proteins. Analytical Cellular Pathology, 2004, 26, 3-11.	0.7	6

#	Article	IF	Citations
1428	Hepatocellular Transport Systems: Basolateral Membrane. , 2004, , 9-20.		0
1429	ABC Transporters. , 2004, , 267-288.		0
1430	Genetic Polymorphisms and Cardiovascular Drug Metabolism. Handbook of Experimental Pharmacology, 2004, , 39-77.	0.9	2
1431	Bile Formation and Cholestasis. , 2004, , 1186-1198.		1
1432	Drug Transporters. Drugs and the Pharmaceutical Sciences, 2004, , 111-136.	0.1	0
1433	Pharmakogenetik. , 2006, , 863-871.		0
1434	Immunoexpression of Multidrug-Resistance Protein 2 and Cyclooxygenase 2 in Medullary Thyroid Carcinomas. Archives of Pathology and Laboratory Medicine, 2006, 130, 1014-1019.	1.2	11
1436	ATP-Dependent Multiple Substrate Transporters. , 2007, , 1-3.		0
1437	Efflux Transporters in the Brain. , 2007, , 461-483.		0
1438	Nanoimaging of Biomolecules Using Near-Field Scanning Optical Microscopy. , 2007, , .		2
1441	Maligne Hodentumoren. , 2009, , 637-738.		0
1443	Clinical Pharmacology and Anticancer Drugs. , 2010, , 11-26.		0
1446	Bile Formation and Cholestasis. , 2011, , 1280-1291.		0
1447	Detoxification. , 2011, , 1101-1104.		0
1448	Outward-Directed Transport. , 2011, , 385-393.		1
1449	Pharmacogenetics of Cancer and DNA Repair Enzymes. , 0, , .		0
1450	The Natural Resistance of Cancer Cells to Natural Inhibitors of Carcinogenesis: A Philosophy Emerging from the Prokaryotic to Eukaryotic Kingdom. New Hope Above Expectation. Journal of Medical Diagnostic Methods, 2012, 01, .	0.0	0
1451	Role of Multidrug Resistance Associated Proteins in Drug Development. , 2012, , 3-35.		2

#	Article	IF	Citations
1452	ABC Transporters in Human Placenta and Their Role in Maternal-Fetal Cholesterol Transfer: ABCA1 Candidate Target. , 0, , .		0
1453	Maligne Hodentumoren. , 2014, , 677-782.		1
1454	RalA-binding Protein 1 is an Important Regulator of Tumor Angiogenesis. Journal of Life Science, 2014, 24, 588-593.	0.2	2
1455	Line Narrowing in Oriented-Sample NMR of Membrane Proteins. Biological Magnetic Resonance, 2015, , 159-185.	0.4	0
1456	Detoxification. , 2015, , 1-4.		0
1457	Detoxification. , 2015, , 1354-1357.		0
1458	Effect of Curcuminoids on MDR-1 Gene Expression in Multidrug Resistance Kbchr-8-5 Human Cervical Cancer Cell Line. International Journal of Pure & Applied Bioscience, 2016, 4, 229-237.	0.1	0
1459	Nanoimaging of Biomolecules Using Near-Field Scanning Optical Microscopy. , 2017, , 127-142.		0
1461	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2018, 128, 3199-3199.	3.9	27
1463	Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells. Oncology Letters, 2020, 20, 1-1.	0.8	19
1464	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. Cancers, 2021, 13, 5480.	1.7	16
1465	Expression and phylogeny of multidrug resistance protein 2 and 4 in African white backed vulture (Gyps africanus). PeerJ, 2020, 8, e10422.	0.9	1
1466	Systemic Therapy for Brain Metastases in Other Primary Cancers (Genitourinary, Gastrointestinal,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		0
1467	Mechanistic Computational Models of Epithelial Cell Transporters-the Adorned Heroes of Pharmacokinetics. Frontiers in Pharmacology, 2021, 12, 780620.	1.6	4
1469	Pathobiological Basis of Treatment Strategies of Germ Cell Tumors. , 2005, , 252-271.		0
1471	Chemosensitization. , 2005, , 335-348.		0
1472	Pumping Out Drugs. , 2006, , 109-117.		1
1473	Maligne Hodentumoren. , 2007, , 521-609.		0

#	Article	IF	Citations
1474	Maligne Hodentumoren. , 2014, , 677-782.		0
1475	Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy, 2003, 1, 47-61.	2.9	215
1478	Photoaffinity labeling of the multidrug resistance protein 2 (ABCC2/cMOAT) with a photoreactive analog of LTC(4). International Journal of Biochemistry and Molecular Biology, 2011, 2, 39-46.	0.1	0
1484	Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. International Journal of Clinical and Experimental Pathology, 2014, 7, 1124-31.	0.5	45
1486	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 23-36.	1.3	59
1488	AML-derived Extracellular Vesicles Confer Chemoresistance to Leukemic Myeloblast Cells by Promoting Drug Export Genes Expression and ROS Inhibition. Iranian Journal of Pharmaceutical Research, 2021, 20, 384-397.	0.3	3
1489	The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?. American Journal of Cancer Research, 2021, 11, 4127-4140.	1.4	2
1490	Organic Cation Transporter I and Na⁺/taurocholate Coâ€Transporting Polypeptide are Involved in Retrorsineâ€and Senecionineâ€Induced Hepatotoxicity in HepaRG cells. Molecular Nutrition and Food Research, 2022, 66, e2100800.	1.5	4
1491	ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics, 2021, 22, 1211-1235.	0.6	12
1492	Metagenomic profiles of the resistome in subtropical estuaries: Co-occurrence patterns, indicative genes, and driving factors. Science of the Total Environment, 2022, 810, 152263.	3.9	38
1493	Multidrug transporters in cancer resistance. , 2002, 4, 167-169.		0
1494	GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells. BMC Pulmonary Medicine, 2022, 22, 36.	0.8	2
1496	Research advances in the role and pharmaceuticals of ATP-binding cassette transporters in autoimmune diseases. Molecular and Cellular Biochemistry, 2022, , 1.	1.4	1
1497	Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 1853.	1.8	13
1498	MRP5 and MRP9 play a concerted role in male reproduction and mitochondrial function. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	9
1499	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer, 2022, 21, 61.	7.9	6
1500	Homology modelling, vHTS, pharmacophore, molecular docking and molecular dynamics studies for the identification of natural compound-derived inhibitor of MRP3 in acute leukaemia treatment. Chemical Papers, 2022, 76, 3729-3757.	1.0	7
1501	Iron Promotes Cardiac Doxorubicin Retention and Toxicity Through Downregulation of the Mitochondrial Exporter ABCB8. Frontiers in Pharmacology, 2022, 13, 817951.	1.6	8

#	Article	IF	Citations
1502	The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review. Acta Neurologica Belgica, 2022, 122, 871-880.	0.5	1
1503	Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics. Neurotherapeutics, 2022, 19, 942-976.	2.1	10
1504	Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma. International Immunopharmacology, 2022, 108, 108722.	1.7	7
1505	The Role of Chloride Channels in the Multidrug Resistance. Membranes, 2022, 12, 38.	1.4	8
1509	Multidrug Resistance in Leukaemia. , 0, , 575-585.		0
1510	Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4. BMC Cancer, 2022, 22, 446.	1.1	6
1512	Natural Products and Their Bioactive Compounds as Chemotherapeutics. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 187-213.	0.1	0
1513	Athelia rolfsii Exopolysaccharide Protection Against Kidney Injury in Lead-Exposed Mice via Nrf2 Signaling Pathway. Biological Trace Element Research, 2023, 201, 1864-1877.	1.9	1
1514	Recent Advances in the Synthesis of Marine-Derived Alkaloids via Enzymatic Reactions. Marine Drugs, 2022, 20, 368.	2.2	1
1515	Drug Carriers: A Review on the Most Used Mathematical Models for Drug Release. Processes, 2022, 10, 1094.	1.3	32
1518	ABC Transporters: An Overview. , 2022, , 1-10.		0
1519	ABC Transporters: Multidrug Resistance-Associated Proteins. , 2022, , 25-32.		0
1520	Dendrimers as carriers for active targeting of brain tumors. , 2022, , 401-430.		0
1521	Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells. Anticancer Research, 2022, 42, 3313-3324.	0.5	1
1522	Cellular landscaping of cisplatin resistance in cervical cancer. Biomedicine and Pharmacotherapy, 2022, 153, 113345.	2.5	22
1523	Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Molecular Cancer Therapeutics, 2004, 3, 545-550.	1.9	35
1525	Temozolomide-Resistant Human T2 and T98G Glioblastoma Cells. Cell and Tissue Biology, 2022, 16, 339-351.	0.2	2
1526	ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis. Cellular Oncology (Dordrecht), 0, , .	2.1	0

#	Article	IF	Citations
1527	OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory. Annual Review of Pharmacology and Toxicology, 2023, 63, 637-660.	4.2	15
1528	Beta-naphthoflavone and doxorubicin synergistically enhance apoptosis in human lung cancer cells by inducing doxorubicin accumulation, mitochondrial ROS generation, and JNK pathway signaling. Biochemical and Biophysical Research Communications, 2022, 635, 37-45.	1.0	1
1529	Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer. Pharmaceutics, 2022, 14, 2218.	2.0	1
1530	Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2). International Journal of Molecular Sciences, 2022, 23, 13261.	1.8	3
1531	Role of ABC Transporters in Cancer Development and Malignant Alteration. Yakugaku Zasshi, 2022, 142, 1201-1225.	0.0	0
1532	FUNKCJE TRANSPORTERÃ“W TYPU ABC. , 2011, 9, 34-40.		1
1533	Estudio de expresiÃ³n y prevalencia del transportador MRP4/ABCC4 en cÃ¡ncer de vesÃcula biliar y vÃas biliares en pacientes del noroeste argentino. , 2022, 24, .		0
1538	The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. Cancers, 2023, 15, 62.	1.7	17
1539	Vascular endothelial cells: a fundamental approach for brain waste clearance. Brain, 2023, 146, 1299-1315.	3.7	4
1540	Inhibitors of ABCG2-mediated multidrug resistance: Lead generation through computer-aided drug design. European Journal of Medicinal Chemistry, 2023, 248, 115070.	2.6	1
1541	Biodiversity: the overlooked source of human health. Trends in Molecular Medicine, 2023, 29, 173-187.	3.5	7
1542	Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment. , 2023, , .		0
1543	Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine and Pharmacotherapy, 2023, 162, 114643.	2.5	26
1544	BIN1 in cancer: biomarker and therapeutic target. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
1545	Reduction in cardiolipin reduces expression of creatine transporter-1 and creatine transport in growing hCMEC/D3 human brain microvessel endothelial cells. Frontiers in Drug Delivery, 0, 3, .	0.4	0
1546	Cellular Compartmentalization, Glutathione Transport and Its Relevance in Some Pathologies. Antioxidants, 2023, 12, 834.	2.2	13
1547	Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance. Advances in Cancer Research, 2023, , .	1.9	0
1548	Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance. International Journal of Molecular Sciences, 2023, 24, 7331.	1.8	2

#	Article	IF	Citations
1570	Resistance of prostate cancer to topoisomerase inhibitors. , 2024, , 157-178.		0
1571	Pharmacogenomics in Drug Metabolism Enzymes and Transporters. , 2023, , 1-47.		0
1577	Cadmium transport by mammalian ATP-binding cassette transporters. BioMetals, 0, , .	1.8	1